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Breast and prostate cancer growth and survival are dependent on signalling via the estrogen receptor 
(ER) and androgen receptor (AR), respectively. However, other steroid receptors such as the 
progesterone receptor (PR), are also implicated in both cancers, and emerging evidence suggests 
considerable crosstalk between these steroid receptors in breast cancer. Investigations into similar 
crosstalk mechanisms are lacking in prostate cancer. As the AR and PR are likely co-expressed in a 
subset of breast and prostate cancers, it is surprising that no studies have investigated crosstalk 
between the AR and PR in these cancers. Both these receptors can activate transcription by binding 
to DNA on a classical response element, termed either the progesterone response element (PRE) when 
the PR is bound, or the classical androgen response element (ARE) when the AR is bound. However, 
the AR can also bind to an AR-selective ARE as well as to the ER binding site, termed the estrogen 
response element (ERE). Whether the PR isoforms, PRA and PRB, can similarly activate the  
AR-selective ARE and ERE is not known. In this study, we investigated whether the PR isoforms, in 
the absence and presence of known PR agonists (synthetic promegestone (R5020), natural 
progesterone (P4), and synthetic progestin medroxyprogesterone acetate (MPA)), could modulate the 
transactivation function of the AR via the above-mentioned response elements in the MDA-MB-231 
breast cancer and PC3 prostate cancer cell lines. The cells were transiently transfected with the 
expression vectors for the AR and/or PR isoforms, together with the applicable promoter-reporter 
constructs. The general trend observed was that both the unliganded and liganded PR isoforms 
augmented AR activity in a cell line-, ligand- and/or promoter-specific manner. Specifically, we 
showed that PRB, both in the absence and presence of PR ligands, generally upregulated AR 
transactivation on the various response elements in the breast and prostate cancer cells. While AR 
transactivation function was also increased by PRA on the selective ARE and ERE, PRA decreased 
AR-mediated transactivation on the classical ARE. We also provide novel evidence that both PR 
isoforms mimic AR activity on the selective ARE and the ERE in both cell lines, which may provide 
a mechanism through which the PR mediates oncogenic effects in both cancers. We did not observe 
cell proliferation in the presence of 5α-dihydrotestosterone (DHT) in either cell line transfected with 
the AR under the experimental conditions used in this study. In summary, even though the results 
from this study are preliminary, we are the first to show that the transactivation function of the AR is 
generally enhanced in the presence of the PR isoforms in both breast and prostate cancer. These 
findings support a potential crosstalk mechanism between the AR and PR isoforms in these cancers. 
Although the precise physiological implications of these results require further investigation, our 
findings contribute to the understanding of crosstalk between steroid receptors, particularly the AR and 
the PR isoforms, and how this may influence breast and prostate cancer cell growth. 
  





Die groei en oorlewing van bors- en prostaatkanker is afhanklik van seine deur onderskeidelik die 
estrogeenreseptor (ER) en androgeenreseptor (AR). Ander steroïedreseptore soos die 
progesteroonreseptor (PR) is egter ook betrokke in beide kankers, en onlangse bewyse stel voor dat 
aansienlike wisselwerking tussen hierdie reseptore in borskanker voorkom. Ondersoeke na 
soortgelyke wisselwerkingsmeganismes in prostaatkanker ontbreek. Aangesien die AR en PR 
waarskynlik saam uitgedruk word in ‘n onderafdeling van bors- en prostaatkankers, is dit verbasend 
dat geen studies die wisselwerking tussen die AR en PR in hierdie kankers ondersoek het nie. Beide 
hierdie reseptore kan transkripsie aktiveer deur te bind aan DNS op ‘n klassieke responselement, 
benoem òf die progesteroonresponselement (PRE) wanneer die PR bind, òf die klassieke 
androgeenresponselement (ARE) wanneer die AR bind. Die AR kan egter ook bind aan ‘n AR 
selektiewe ARE asook die ER bindingsarea, benoem die estrogeenresponselement (ERE). Dit is 
onbekend of die PR isoforme, PRA en PRB, die AR selektiewe ARE en ERE soorgelyk kan aktiveer. 
In hierdie studie, het ons ondersoek of the PR isoforme, in die afwesigheid en teenwoordigheid van 
bekende PR agoniste (sintetiese promegestoon (R5020), natuurlike progesteroon (P4), en die 
sintetiese progestien medroksieprogesteroonasetaat (MPA)), die transaktiveringsfunksie van die AR 
deur die bogenoemde responselemente kon wysig in die MDA-MB-231 borskanker- en PC3 
prostaatkankersellyne. Die selle was tydelik getransfekteer met die uitdrukkingsvektor vir die AR 
en/of PR isoforme, saam met die toepaslike promotor-rapporteerder konstrukte. Die algemene 
tendens wat waargeneem is, was dat beide die ligandlose en ligand-gebonde PR isoforme die 
aktiwiteit van die AR verhoog het in ‘n sellyn-, ligand- en/of promotor-spesifieke manier. Ons het 
spesifiek getoon dat PRB, beide in die afwesigheid en teenwoordigheid van PR ligande, in die 
algemeen AR transaktivering op verskeie responselemente in die bors- en prostaatkankerselle 
opreguleer. Alhoewel die AR transaktiveringsfunksie ook deur PRA verhoog was op die selektiewe 
ARE en ERE, het PRA die AR-bemiddelde transaktivering op die klassieke ARE verlaag. Ons het 
ook nuwe bewyse voorsien dat beide PR isoforme die aktiwiteit van die AR naboots op die seletiewe 
ARE en ERE in beide sellyne, wat ‘n meganisme mag voorsien waardeur die PR onkogeniese effekte 
in beide kankers kan uitvoer. Onder hierdie gebruikte eksperimentele kondisies, het ons geen 
selproliferasie in die teenwoordigheid van 5α-dihidrotestosteroon (DHT) in enige sellyn 
getransfekteer met die AR waargeneem nie. In opsomming, alhoewel die resultate van hierdie studie 
voorlopig is, is ons die eerste om te toon dat die transaktiveringfunksie van die AR oor die algemeen 
verhoog is in die teenwoordigheid van die PR isoforme in beide bors- en prostaatkanker. Hierdie 
bevindinge ondersteun die potensiële wisselwerkingsmeganisme tussen die AR en PR isoforme in 
hierdie kankers. Alhoewel die presiese fisiologiese implikasies van hierdie resultate verdere 




ondersoek verlang, dra ons bevindinge by tot die begrip van wisselwerking tussen steroïdreseptore, 
veral die AR en die PR isoforme, en hoe dit bors- en prostaankankergroei mag beïnvloed. 
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Globally, breast cancer is the most common cancer in women, and prostate cancer the second most 
common cancer in men (Ferlay et al., 2015; Torre et al., 2015). Both breast and prostate cancer are 
hormone-dependent malignancies, relying on steroid hormones such as estrogens and androgens, 
respectively, for survival (Sommer and Fuqua, 2001; Shafi et al., 2013). Indeed, estrogen and its 
cognate receptor, the estrogen receptor (ER), are considered the main etiological factors contributing 
to breast cancer development (Sommer and Fuqua, 2001). Prostate cancer, on the other hand, is 
dependent on androgen signalling via its cognate receptor, the androgen receptor (AR) (Lee et al., 
2003; Azzouni and Mohler, 2012). Current therapies for breast cancer thus target estrogen 
biosynthesis and the ER, while prostate cancer treatments target the AR and androgen biosynthesis 
(Nagaraj and Ma, 2015; Attard et al., 2016). Resistance to therapy, however, is a pressing concern in 
both breast and prostate cancer (Rau et al., 2005). Interestingly, the ER subtype, ERα, is also 
implicated in prostate cancer development and progression (Bonkhoff et al., 1999). Similarly, AR 
expression in ER-negative breast cancer tumours is associated with breast cancer development (Peters 
et al., 2009). Numerous studies are thus focusing on the role of estrogens and the ER in prostate 
cancer and androgens and the AR in breast cancer (Nelles et al., 2011; Cochrane et al., 2014; Yeh et 
al., 2014; Omoto and Iwase, 2015; Wellberg et al., 2017). In addition to the ER and AR, other steroid 
receptors such as the progesterone receptor (PR) are also expressed in breast and prostate tumours 
(Bonkhoff and Berges, 2009; Knutson and Lange, 2014). Considering that the PR is expressed in both 
breast and prostate cancer, and that studies have shown that the PR plays an important role in both 
diseases (Bonkhoff et al., 2001; Mc Cormack et al., 2007; Grindstad et al., 2015), it is surprising that 
current treatments do not target this receptor (Rau et al., 2005). Interestingly, a number of studies 
have found that steroid receptor crosstalk between ERα and the AR, as well as ERα and the PR, plays 
an integral role in breast cancer (Kumar et al., 1994; Panet-Raymond et al., 2000; Peters et al., 2009; 
Muthusamy et al., 2011; Grubisha and DeFranco, 2013; Cochrane et al., 2014; D’Amato et al., 2016). 
Similar studies investigating steroid receptor crosstalk mechanisms in prostate cancer are scarce. 
Whether crosstalk between the PR and AR occurs in breast and prostate cancer, and the implications 
of such crosstalk, has not been investigated. Understanding crosstalk between these steroid receptor 
signalling pathways may therefore contribute to the development of new improved therapies for the 
treatment of breast and prostate cancer. The primary aim of this review is to describe the mechanism 
of action of the AR and PR, and their ligands, in breast and prostate cancer, highlighting similarities 
and differences. Considering the increasing importance of steroid receptor crosstalk in breast cancer, 
known crosstalk mechanisms and their implications will also be discussed.  




 General structure and mechanism of action of steroid receptors 
The steroid hormone receptor family includes the glucocorticoid receptor (GR), mineralocorticoid 
receptor (MR), ER, PR and AR (Tata, 2002; Robinson-Rechavi, 2003). These receptors are ligand-
activated transcription factors with a highly conserved structure (Tata, 2002), containing an upstream 
N-terminal transactivation domain (NTD) with activation function-1 (AF-1), a central DNA binding 
domain (DBD), a downstream hinge region (h) and a C- terminal ligand binding domain (LBD) which 
contains the activation function-2 (AF-2) domain (Fig. 1.1). The AF-1 domain is responsible for 
ligand-independent activation of the receptors, while the AF-2 domain mediates ligand-dependent 
effects (Wärnmark et al., 2003; Lavery and McEwan, 2005).  
The ER exists as two main subtypes, ERα and ERβ, which are expressed from two different genes 
(Kuiper et al., 1996). Although ERα and ERβ only share a 47% overall sequence identity, the DBD 
domain is highly conserved and has a 94% sequence identity (Muramatsu and Inoue, 2000). Similarly, 
the PR exists as two isoforms, PRA and PRB, which are transcribed from two different promoters of 
a single gene (Kastner et al., 1990). The PR isoforms are identical in sequence except that PRB 
contains an additional 164 amino acids in the NTD. An additional AF domain, namely activation 
function-3 (AF-3), is found in this NTD, rendering PRB more transcriptionally active than PRA in 
the presence of ligand (Sartorius et al., 1994). Notably, this difference in activity is due to the fact 
that the ligand induces a conformational change in PRB such that the AF subdomains are able to 
functionally interact (Tung et al., 2001; Takimoto et al., 2003). Although two separate isoforms 
transcribed from the same gene have also been reported for the AR, these isoforms are not well 
described (Lavery and McEwan, 2005; Azzouni and Mohler, 2012).  
When comparing the structures of the ER, PR and AR (Fig. 1.1), it is clear that the PR isoforms are 
more similar to the AR as they share a 82% and 55% amino acid sequence identity in the DBD and 
LBD, respectively (Gao et al., 2005). In comparison, the ER subtypes are the most distinct (Gao et 
al., 2005) with the amino acid sequence identity of ERα and ERβ to the AR only 59% and 22-25% in 
the DBD and LBD, respectively (Gao et al., 2005). Furthermore, although not indicated in figure 1.1, 
the PR shares a 54% and 23% amino acid sequence identity with the ER subtypes in the DBD and 
LBD, respectively (Ruff et al., 2000). As the PR and AR share a high degree of structural homology, 
these receptors recognize and bind similar DNA sequences, while the ER subtypes bind distinct DNA 
motifs (Beato, 1989). 
 





Figure 1.1: Comparison of the structural domains of the AR, PR isoforms and ER subtypes. The numbers indicated 
within the structure represent the amino acid sequence identity of each domain to the AR (set as 100%), while those 
outside of the structure represent the total number of amino acids. The N-terminal transactivation domain (NTD) contains 
the activation function-1 (AF-1) domain, while the activation function-2 (AF-2) domain is located in the LBD. The 
additional activation function 3 (AF-3) domain in PRB is also shown. The DNA-binding domain (DBD) confers the 
sequence-specificity of protein-DNA interactions, while the downstream hinge region (h) and ligand-binding domain 
(LBD) contribute to the ligand-specificity of the receptors (Tata, 2002). Figure adapted from: Tata, 2002; Robinson-
Rechavi, 2003; Gao et al., 2005. 
Steroid receptors are generally located in the nucleus, bound to chaperone proteins which stabilise 
and prevent degradation of the receptor (Fig. 1.2) (Pratt et al., 2004). While the unliganded AR and 
PRB are primarily localised in the cytoplasm, the unliganded ER subtypes and PRA are present in 
the nucleus (Leslie et al., 2005; Echeverria and Picard, 2010). Upon ligand binding, steroid receptors 
undergo a conformational change and translocate to the nucleus where they can activate 
(transactivation) or repress (transrepression) gene expression (Tata, 2002; Robinson-Rechavi, 2003). 
During transactivation, the steroid receptor binds as a dimer, directly to the DNA, at specific 
sequences termed steroid response elements (Tata 2002, Robinson 2003). Transrepression on the 
other hand is a process whereby the liganded steroid receptor tethers to other DNA-bound 




transcription factors, such as nuclear factor kappa B (NFκB) (Tata, 2002; Robinson-Rechavi, 2003). 
The transcriptional activity of the steroid receptor is determined by its conformation upon ligand 
binding, as this structural change promotes or prevents its interaction with co-regulators  (Beato et 
al., 1996). For transactivation, co-activators and components of the basal transcription machinery are 
recruited to the promoters of target genes to activate transcription, while co-repressors are recruited 
during transrepression to repress transcription  (Beato et al., 1996; Hager et al., 2009). 
In this thesis we will focus on the transactivation of gene expression via the AR and how it is 
influenced by the PR isoforms. In general, all steroid receptors, except the ER, activate transcription 
by binding to a classical steroid response element with the palindromic sequence 
GGTACAnnnTGTTCT (Beato, 1989). This sequence is termed a progesterone response element 
(PRE) for the PR or classical androgen response element (ARE) for the AR (Schauwaers et al., 2007; 
Africander et al., 2014). Additionally, the AR also recognizes a direct repeat sequence  
(GGCTCTTTCAGTTC) which has been termed the AR-selective ARE, since it was not activated by 
the GR (Sui et al., 1999; Claessens and Gewirth, 2004; Schauwaers et al., 2007). The ER on the other 
hand, specifically recognizes the constrained, palindomic estrogen response element (ERE) sequence 
(AGGTCAgagTGACCT) (Belandia and Parker, 2000).  
 Steroid receptors: Key role players in the development of breast and prostate 
cancer 
1.3.1  Estrogens and the ER subtypes 
Both the ERα and ERβ are involved in the development of the normal breast and prostate, as well as 
the cancerous breast and prostate (Horvath et al., 2001; Förster et al., 2002; Palmieri et al., 2002; 
Attia and Ederveen, 2012; Murphy and Leygue, 2012; Cheng et al., 2013; Omoto and Iwase, 2015). 
However, it is well-known that these two receptors display differential roles in the regulation of 
physiological responses (Palmieri et al., 2002; Attia and Ederveen, 2012; Cheng et al., 2013). 
Both ERα and ERβ are present in the normal mammary gland (Murphy and Leygue, 2012). ERα is 
largely responsible for mammary gland development (Förster et al., 2002; Palmieri et al., 2002; 
Murphy and Leygue, 2012; Cheng et al., 2013), while ERβ mediates the later stages of mammary 
gland  
 





Figure 1.2: An illustration of the general mechanism of action of steroid receptors. A steroid hormone (S) diffuses 
across the cell membrane and binds to its cognate steroid receptor (SR), causing a conformational change in the receptor 
and the dissociation of chaperone proteins. The steroid-bound steroid receptor translocates to the nucleus where it can 
activate transcription (transactivation) by directly binding as a dimer to a steroid response element (SRE), or repress gene 
expression (transrepression) by tethering as a monomer to other DNA-bound transcription factors, such as NFκB. Figure 
adapted from: Africander et al., 2011. 
differentiation and is the more abundantly expressed ER subtype (Förster et al., 2002). In breast 
cancer tissue, however, ERα levels are upregulated, while ERβ expression is decreased (Khan et al., 
1994, 2002; Lawson et al., 1999; Zhao et al., 2003; Murphy and Leygue, 2012). Although both ERα 
and ERβ are also expressed in the developing prostate, and ERα is reported to be vital for normal 
prostate development, ERα is less abundant than ERβ in the normal adult prostate (Prins and Birch, 
1997; Horvath et al., 2001; Prins et al., 2001a; Omoto et al., 2005). The reverse is true in prostate 
cancer, where ERα is expressed in about 60% of prostate cancer lesions and ERβ in less than 10% 
(Latil et al., 2001; Leav et al., 2001; Cheng et al., 2004; Yang et al., 2007; Bonkhoff and Berges, 
2009; Megas et al., 2015). The high expression of ERα is associated with higher tumour grade, while 
the decrease in ERβ expression promotes changes in cell morphology leading to increased tumour 
proliferation (Horvath et al., 2001; Latil et al., 2001; Leav et al., 2001; Pasquali et al., 2001; Royuela 
et al., 2001; Fixemer et al., 2003; Zhao et al., 2003; Cheng et al., 2004). Taken together, the increases 
in ERα expression and decreases in ERβ expression in both breast and prostate cancer, suggests that 
ERα ultimately sustains tumour growth.  
It is well-known that estrogens and the ER are key role players in breast cancer development (Ali and 
Coombes, 2000; Turner et al., 2017). For example, when bound to the most biologically active 




estrogen, 17β-estradiol (E2), ERα mediates proliferation of breast cancer cell lines by increasing the 
expression of cell cycle regulators such as p21 and cyclin D1, as well as migration by decreasing the 
expression of cell adhesion proteins (Castro-Rivera et al., 2001; Liu et al., 2002; Alao, 2007; Liao et 
al., 2014). The role of ERβ, however, is dependent on the absence and presence of ERα. For example, 
although numerous studies have shown that ERβ is anti-proliferative in cells expressing ERα (Castro-
Rivera et al., 2001; Liu et al., 2002; Alao, 2007), it is reported to be proliferative in ERα-negative 
breast cancer cells (Pettersson et al., 2000; Liu et al., 2002; Matthews and Gustafsson, 2003). It has 
been proposed that ERβ inhibits ERα-mediated transcription due to the formation of ERα and ERβ 
heterodimers (Pettersson et al., 2000; Liu et al., 2002; Lindberg et al., 2003; Paruthiyil et al., 2004; 
Murphy and Leygue, 2012). The roles of ERα and ERβ have been the topic of numerous reviews (Ali 
and Coombes, 2000; Gross and Yee, 2002; Palmieri et al., 2002; Matthews and Gustafsson, 2003; 
Mohamed et al., 2013), while similar reviews on their roles in prostate cancer are limited. We will 
thus focus mainly on the role of ERα and ERβ in prostate cancer for the rest of this section. 
From the above studies, it appears that ERα and ERβ have similar roles in breast and prostate cancer 
(Horvath et al., 2001; Attia and Ederveen, 2012; Omoto and Iwase, 2015). The functions of these 
receptors in prostate cancer have been highlighted by studies in mice with prostate cancer tumours in 
which either ER subtype was knocked down (Ricke et al., 2007). For example, a study using  
ERα knockout mice (αERKO) and ERβ knockout mice (βERKO) demonstrated that the αERKO mice 
prostates showed tumour regression, suggesting that ERα mediates oncogenic effects in the prostate, 
while the findings with the βERKO mice showed that ERβ prevents prostate cancer progression 
(Ricke et al., 2007). In addition, ERα has been shown to mediate various oncogenic functions in 
prostate cancer by increasing the expression of the pS2 gene, a well-studied ERE-containing gene in 
breast cancer, known to be associated with increased cell adhesion, migration and invasion (Kim et 
al., 2000). As in breast cancer, the role of ERβ in prostate cancer is dependent on the absence or 
presence of ERα. For example, while the expression of ERβ is considered to be anti-oncogenic in 
prostate cancer expressing ERα (Bonkhoff and Berges, 2009), it has been reported to mediate 
oncogenic effects in ERα-negative prostate cancer (Barkhem et al., 1998; Shazer et al., 2006). In 
addition, it has been shown that the growth of androgen-dependent and androgen-independent 
prostate cancer xenografts expressing only ERβ is inhibited in the presence of a pure ERβ antagonist 
(Barkhem et al., 1998; Shazer et al., 2006). 
Numerous other studies have indicated the divergent roles of ERα and ERβ when co-expressed in 
prostate cancer. Most studies show that ERα stimulates prostate cancer cell proliferation, while ERβ 
inhibits ERα-mediated cell proliferation (vom Saal et al., 1997; McLachlan et al., 1998; Strauss et al., 
1998; Prins et al., 2001a, 2001b, 2006, 2007; Attia and Ederveen, 2012). However, differential effects 




are not limited to proliferation. For example, it has been shown that the occurrence of the 
TMPRSS:ERG gene fusion in prostate cancer is increased in the presence of the ERα-specific agonist 
proprylpyrazole triol, but decreased in the presence of the ERβ-specific agonist diarylpropionitrile 
(Setlur et al., 2008). The TMPRSS:ERG gene is a fusion of the TMPRSS2 and E26 transformation-
specific (ETS)-regulated (ERG) genes that occurs in 60% of prostate cancer tumours and ultimately 
leads to increases in prostate cancer cell proliferation and invasion (Setlur et al., 2008). In addition, 
while ERα mediated increases in cell invasion and proliferation, but decreases in apoptosis in the  
DU-145 prostatic carcinoma cell line, these effects were inhibited by ERβ (Cheng et al., 2004).  
1.3.1.1 Targeting the ER in breast and prostate cancer 
Breast cancer treatments focus on preventing the activation of the ER either by blocking the 
cytochrome P450 aromatase enzyme (CYP19A1) required for the biosynthesis of estrogen with 
aromatase inhibitors, or by blocking the ER using ER antagonists or selective ER modulators 
(SERMs), or by degrading the ER protein with selective ER downregulators (SERDs) (reviewed in 
Rau et al., 2005; Nagaraj and Ma, 2015). For example, although the SERM, tamoxifen, binds to the 
ER and allows the tamoxifen-bound ER to translocate to the nucleus, the ER cannot activate genes 
required for estrogen-mediated cell proliferation (Piccart et al., 2003). In contrast, the SERD, 
fulvestrant, downregulates the ERα protein thereby decreasing ERα activation by estrogens (Osborne 
et al., 2004; Agrawal et al., 2016). However, many women develop resistance to these treatments 
(Rau et al., 2005; Nagaraj and Ma, 2015), and thus current research is aimed at the development of 
improved therapies, such as compounds that have both ERα-selective antagonist and ERβ-selective 
agonist activity (Visser et al., 2013).  
Although estrogens have been implicated in prostate cancer, these hormones have paradoxically been 
used in clinical trials of prostate cancer as a hypothalamus-pituitary-adrenal (HPA)-axis suppressor 
to decrease androgen production. Notably, the synthetic estrogen, diethylstilbestrol (DES) has formed 
part of certain ADT regimes, although it was not well tolerated (Citrin et al., 1991; Nelles et al., 
2011). In addition, studies testing the use of 2-methoxyestradiol in castration-resistant prostate cancer 
(CRPC) patients have achieved mixed results. One study found that although the drug was well-
tolerated, it did not confer any significant clinical benefits, while another study observed between a 
20-40% decrease in the levels of the marker of prostate cancer, prostate-specific antigen (PSA) 
(Sweeney et al., 2005; Harrison et al., 2011). 
Multiple SERMs have also been investigated for the treatment of prostate cancer (Bergan et al., 1999; 
Stein et al., 2001; Hamilton et al., 2003; Lissoni et al., 2005; Price et al., 2006). For example, 20% of 
CRPC patients treated with tamoxifen and 27% of androgen-independent prostate cancer patients 




treated with raloxifene showed tumour regression after treatment (Bergan et al., 1999; Shazer et al., 
2006). In addition, tamoxifen treatment caused a decline in PSA levels in 29% of patients in a phase 
II study of metastatic CRPC patients (Lissoni et al., 2005). Findings from clinical trials investigating 
prostate cancer treatment with the SERM toremifene, have shown contradictory results. One trial in 
androgen-independent prostate cancer patients showed that toremifene did not result in any clinical 
benefit (Stein et al., 2001), while a later clinical trial showed that the risk and incidence of prostate 
cancer development was decreased with toremifene treatment (Price et al., 2006). However, it should 
be noted that the Stein et al. (2001) investigation showing no clinical benefit consisted of a much 
smaller cohort of only 15 patients, while the trial indicating benefit had a cohort of 447 patients (Price 
et al., 2006). 
In summary, although breast cancer treatments that typically target estrogen synthesis or the ER are 
mostly effective, resistance is known to develop in some patients. While the ER is also targeted in 
prostate cancer, findings from the few clinical studies are contradictory. It is thus evident that more 
studies are required to investigate ER targeted therapies in both breast and prostate cancer.  
1.3.2  Androgens and the AR 
Androgens and the AR are vital for male physiology, and play a role in the development of the normal 
prostate and prostate cancer (Proverbs-Singh et al., 2015). The AR is expressed throughout the normal 
prostatic epithelium, and is upregulated during cancer progression when compared to the normal 
prostate (Latil et al., 2001; Qiu et al., 2008; Zeng et al., 2010; Barboro et al., 2014; Proverbs-Singh 
et al., 2015). In fact, high expression levels of the AR in prostate cancer are associated with disease 
progression and decreased disease-free survival (Lee et al., 2003).  
Androgens acting via the AR are known to mediate prostate cancer progression via a number of 
mechanisms, such as increasing cell proliferation while limiting apoptosis (Azzouni and Mohler, 
2012; Attard et al., 2016). One of the most well-studied mechanisms through which the AR induces 
proliferation, albeit indirectly, is via its control of the TMPRSS2 gene (Robinson et al., 2015). 
Although the function of this gene is not well-described, it is known that 60% of prostate cancers 
exhibit chromosomal translocations leading to TMPRSS2:ERG gene fusion (Robinson et al., 2015). 
Induction of the TMPRSS2 gene via the AR leads to increased ERG expression, and ERG in turn 
increases the expression of the oncogene, c-myc, which is associated with increased cell proliferation 
(Hoffman and Liebermann, 2008; Sun et al., 2008; Karantanos et al., 2013). A role for the AR in 
prostate cancer cell proliferation has been shown in various prostate cancer cell lines and mouse 
models in which cell proliferation was inhibited in the presence of the AR antagonist, bicalutamide, 




or by AR silencing using siRNA (Colombel et al., 1993; Furuya et al., 1996; Gleave et al., 1999; Jayo 
et al., 2000; Yang et al., 2005; Arnold et al., 2007; Peters et al., 2011; Zhou et al., 2015; Komaragiri 
et al., 2016; Bae et al., 2017; Wang et al., 2017). Similarly, the importance of androgens are 
highlighted by studies showing that androgen signalling and androgen-mediated tumour proliferation 
are maintained in patients who become resistant to androgen deprivation therapy, the first-line 
treatment for advanced prostate cancer (Litvinov et al., 2003; Yang et al., 2005; Hoang et al., 2015).  
Androgens acting via the AR have also been shown to decrease apoptosis. Apoptosis refers to the 
process of programmed cell death that occurs during normal cell development and ageing, and as a 
defence mechanism during cell damage, to maintain healthy cell populations in tissues (Elmore, 
2007). In cancer however, cells develop mechanisms to evade apoptosis and thereby promote the 
survival of the cancerous cell (Elmore, 2007). It has been shown that treatment with the potent natural 
androgen 5α-dihydrotestosterone (DHT), acting via the AR, significantly decreased the expression of 
the apoptotic-promoting proteins, p53 and caspase-2, and increased the expression of the anti-
apoptotic bcl-2 in several prostate cancer cell lines, including the LNCaP and VCaP cell lines 
(Colombel et al., 1993; Furuya et al., 1996; Gleave et al., 1999; Nantermet et al., 2004; Rokhlin et 
al., 2005; Komaragiri et al., 2016; Bae et al., 2017; Wang et al., 2017). Another study has indicated 
that DHT signalling via the AR prevents apoptosis by inhibiting a kinase pathway in the LNCaP cell 
line, which was reversed by treatment with bicalutamide and AR gene silencing (Lorenzo and 
Saatcioglu, 2008). In summary, it is evident that the AR contributes to prostate cancer by promoting 
prostate cancer cell growth and preventing apoptosis. Since the role of the AR in prostate cancer has 
been extensively reviewed, we will only focus on the AR in the context of breast cancer in the next 
section. 
The role of androgens and the AR are not limited to prostate cancer, and have also been noted in the 
development of the normal and cancerous breast (Proverbs-Singh et al., 2015). The AR is abundantly 
expressed in the normal mammary epithelium (Hickey et al., 2012; Tarulli et al., 2014; Proverbs-
Singh et al., 2015), while its expression in breast cancer varies depending on the breast cancer 
subtype. Specifically, about 25% of triple-negative breast cancer (TNBC) tumours express the AR 
(Micello et al., 2010; Niemeier et al., 2010; Park et al., 2010; Loibl et al., 2011; Wang et al., 2016), 
while it is expressed in 80% of ER-positive breast cancers (Agoff et al., 2003; Ogawa et al., 2008; 
Niemeier et al., 2010; Park et al., 2010; Loibl et al., 2011). The role of androgens and the AR in 
normal and cancerous breast development is complex. Normal breast growth is suppressed in 
prepubescent females who have high circulating androgens due to adrenal hyperplasia, suggesting an 
inhibitory role of androgens in breast cell proliferation (Forsbach et al., 2000). In support of this, 
numerous other studies have demonstrated inhibitory effects of androgens and the AR in breast 




development of pubescent and adult females (Dürnberger and Kratochwil, 1980; Pashko et al., 1981; 
Casey and Wilson, 1984; Jayo et al., 2000; Dimitrakakis et al., 2003; Peters et al., 2011; Cheng et al., 
2013). In breast cancer, however, the role of the AR seems to change depending on the presence of 
ERα. TNBC patients expressing the AR showed improved survival upon treatment with the AR 
antagonist, enzalutamide, suggesting that the AR mediates tumorigenic effects in the context of 
TNBC (Hickey et al., 2012; Lehmann and Pietenpol, 2014; Lim et al., 2014; McNamara et al., 2014; 
Barton et al., 2015; Lyons and Traina, 2017). In agreement with this study showing an oncogenic role 
for the AR in TNBC, proliferation studies in the ER-/AR+ MDA-MB-453 TNBC cell line showed that 
DHT-induced proliferation was inhibited by the AR antagonists hydroxyflutamide and enzalutamide 
(Birrell et al., 1995a; Cochrane et al., 2014). Moreover, the gene signature of this cell line has been 
shown to be similar to that of ER-positive breast cancer cell lines, such as the T47D and MCF-7 cell 
lines (Cochrane et al., 2014). This phenomenon is due to the AR activating similar gene sets as the 
oncogenic ERα (Cochrane et al., 2014), and suggests that the AR mimics the activity of ERα in  
ERα-negative cancers. Indeed, it has been shown that the activated AR, like activated ERα, can bind 
to the ERE (Peters et al., 2009).  
In contrast to the studies showing that the AR may mediate oncogenic effects in AR-positive TNBC, 
experimental studies investigating the role of the AR in ERα-positive breast cancer cell lines mostly 
suggest that the AR protects against cell proliferation (Poulin et al., 1988; Birrell et al., 1995a; Szelei 
et al., 1997; Ortmann et al., 2002; Macedo et al., 2006; Cops et al., 2008). For example, numerous 
studies have shown that proliferation of the ER+/AR+ positive MCF-7, T47D and ZR-75-1 breast 
cancer cell lines is decreased in the presence of the synthetic androgen mibolerone (Mib), as well as 
the natural androgens DHT and testosterone (Poulin et al., 1988; Birrell et al., 1995a; Szelei et al., 
1997; Ortmann et al., 2002; Macedo et al., 2006; Cops et al., 2008). In addition, treatment with DHT 
has been shown to promote apoptosis in the MCF-7, T47D and ZR-75-1 breast cancer cell lines by 
suppressing the expression of the anti-apoptotic bcl-2 gene (Kandouz et al., 1999; Lapointe et al., 
1999; Macedo et al., 2006). However, as previously mentioned at least one study has shown that 
treatment with DHT and Mib increased MCF-7 cell proliferation via the AR (Birrell et al., 1995a).  
Finally, a protective role of the AR in ER-positive breast cancer progression has also been shown by 
a comparative study between AR knockout (ARKO) female mice and AR wild-type female mice 
(Simanainen et al., 2012). This study showed that the ARKO mice developed mammary tumours 
much sooner than wild-type mice (Simanainen et al., 2012). In contrast to this study, other studies 
have suggested that the AR may promote the growth of ER-positive breast cancer cell lines as well 
as ER-positive tumours (De Amicis et al., 2010; Wellberg et al., 2017). For example, AR 
overexpression in the ER-positive MCF-7 cell line has been shown to abrogate tamoxifen-mediated 




repression of cell proliferation and increased anchorage-independent growth (De Amicis et al., 2010). 
Involvement of the AR in these abrogating-effects was confirmed when the effects were reversed in 
the presence of the AR antagonist, bicalutamide (De Amicis et al., 2010).  
Taken together, the data suggests that the AR mediates proliferation and maintains tumour function 
in prostate cancer and TNBC. While most studies suggest that the AR may be protective against  
ERα-mediated oncogenicity, some studies have suggested that the AR may in fact not be protective 
in this context, as it can also mediate increases in proliferation. More studies are thus required to 
elucidate the precise role of the AR in ERα-positive breast cancer.  
1.3.2.1 Targeting the AR in breast and prostate cancer 
Therapies currently available for prostate cancer target androgen biosynthesis or the AR to prevent 
tumour progression. In addition, androgen deprivation therapy is used to treat patients with advanced 
or metastatic prostate cancer (Harris et al., 2009), and is often administered in combination with the 
AR antagonists flutamide or bicalutamide (Harris et al., 2009). Antagonists inhibit the activation of 
AR by preventing nuclear translocation (Brogden and Chrisp, 1991; Masiello et al., 2002; Rau et al., 
2005; Osguthorpe and Hagler, 2011). In response to this treatment, patients initially show a significant 
decline in circulating testosterone and levels of the prostate cancer marker, PSA, indicating clinical 
and biochemical remission (Zlotta and Debruyne, 2005; Ross, 2008). However, this treatment is only 
temporarily effective and almost all patients develop CRPC, which is a far more aggressive and fatal 
malignancy (Ross, 2008; Azzouni and Mohler, 2012). Another AR antagonist, enzalutamide, has 
shown promising results in several clinical trials of CRPC patients, as it significantly reduced PSA 
levels, prolonged survival and improved quality of life in these patients  (Scher et al., 2012; 
Bhattacharya et al., 2015; James et al., 2016; Kim et al., 2016). Finally, abiraterone acetate, the 
inhibitor of the enzyme cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17A1) which is 
essential for androgen biosynthesis, has been shown to reduce PSA levels by 50% and significantly 
improve survival in phase I and II clinical trials (Scher et al., 2008; Ryan et al., 2015; Poon et al., 
2016). However, as abiraterone acetate also prevents the endogenous production of glucocorticoids, 
patients receiving this treatment are additionally administered synthetic glucocorticoids (Auchus et 
al., 2014).  
Various clinical trials have also investigated the AR as a target for treatment of both AR-positive 
TNBC and ER-positive breast cancers, using both AR agonists and antagonists (reviewed in Anestis 
et al., 2015). For example, findings from a trial investigating treatment of AR-positive TNBC with 
the AR antagonist, bicalutamide, indicate that 20% of patients achieved complete tumour regression 
after therapy (Gucalp et al., 2013), suggesting that bicalutamide provides significant clinical benefit 




for TNBC. Post-menopausal ER-positive breast cancer patients treated with a synthetic, non-
metabolisable AR agonist, fluoxymesterone, in combination with the SERM, tamoxifen, have also 
shown clinical benefit as this combination treatment improved remission rates when compared to 
treatment with tamoxifen alone (Tormey et al., 1983; Ingle et al., 1991). In contrast, current phase II 
clinical studies investigating the use of the AR antagonist, enzalutamide, or the CYP17A1 inhibitor, 
abiraterone acetate, in combination with the aromatase inhibitor, exemestane, have thus far not shown 
any clinical benefit when compared to treatment with exemestane alone (O’Shaughnessy et al., 2014; 
Schwartzberg et al., 2014). 
Medroxyprogesterone acetate (MPA) is a synthetic progestin that was designed to mimic the activity 
of the natural progesterone (P4) via the PR (Croxatto, 2005). Although low doses of MPA used in 
hormone therapy (HT) are associated with increased breast cancer risk, higher doses have been 
effectively used in the treatment of advanced ER-positive breast cancer before or after tamoxifen 
failure (Focan et al., 2004; Zaucha et al., 2004). In addition, clinical studies have shown that AR 
expression is required for the response to MPA treatment after tamoxifen (Birrell et al., 1995b; Bentel 
et al., 1999; Buchanan et al., 2005). This is not surprising as MPA is known to elicit potent agonist 
activity via the AR (Africander et al., 2014; Louw-du Toit et al., 2017), suggesting that it is the 
androgenic properties of MPA that confer these clinical benefits in advanced breast cancer (Birrell et 
al., 1995b; Bentel et al., 1999; Buchanan et al., 2005; Carroll et al., 2017).  
In summary, although resistance to prostate cancer therapy does often occur, it is clear that targeting 
AR activity is sufficient to limit prostate cancer progression in the short-term. In breast cancer, 
however, results from clinical studies targeting the AR are more complex, and indicate that more 
studies are required to elucidate the intricacies of AR signalling in breast cancer. 
1.3.3  Progestogens and the PR 
Progestogens are a group of PR ligands, that include natural P4 as well as progestins, which are 
synthetic compounds designed to mimic the actions of P4 via the PR (Campagnoli et al., 2005; Sitruk-
Ware, 2008). Progestins are widely used in menopausal HT and in contraceptives (Campagnoli et al., 
2005; Sitruk-Ware, 2008), and have been linked to increased risk of breast cancer (Beral and Million 
Women Study Collaborators, 2003; Chlebowski et al., 2013, 2009, 2003; Collaborative Group on 
Hormonal Factors in Breast Cancer, 1996; Fabre et al., 2007; Hunter et al., 2010; Li et al., 2012; 
Santen, 2014). Interestingly, the link between the progestin MPA and breast cancer was shown more 
than three decades ago when 80% of BALB/c mice developed mammary tumours weeks after 
treatment with MPA (Lanari et al., 1986). In contrast, most studies have suggested that P4 does not 




influence breast cancer risk (Carroll et al., 2017; Fournier et al., 2008, 2005; Lieberman and Curtis, 
2017). 
Until recently, the PR was considered as only a marker of ER functionality in breast cancer, since the 
ER is known to regulate PR expression by binding to an ERE in the promoter of the PR gene (Peters 
et al., 2009; Ravdin et al., 1992). Although the PR is expressed in 60-70% of breast cancers (Allred 
et al., 2012; Pichon et al., 1996; Thorpe, 1988; Wenger et al., 1993), its exact role in breast cancer is 
still an area of ongoing research. However, some studies in metastatic breast cancer patients on 
tamoxifen therapy have suggested that PR expression may predict success of endocrine therapy and 
survival, suggesting that the PR is a positive prognostic factor in breast cancer (Bardou et al., 2003; 
Elledge et al., 2000; Fisher et al., 1988; Kurozumi et al., 2017; Mohsin et al., 2004; Pertschuk et al., 
1990, 1988; Sato et al., 2016; Snell et al., 2017). In contrast to these studies, another study has 
suggested that the PR is a poor prognostic factor and may predict disease recurrence in invasive breast 
cancer patients (Onoda et al., 2015). Moreover, studies investigating the role of the PR in breast 
cancer rarely distinguish between the PR isoforms, PRA and PRB. Such studies are important as it is 
known that the ratio of PRA to PRB is dysregulated in breast cancer, and that these isoforms may 
activate similar or different gene sets (Hopp, 2004; Kariagina et al., 2008; Sartorius et al., 1994). For 
example, ~50% of the total P4-regulated genes in the T47D breast cancer cell line are regulated by 
PRB, while ~30% are regulated by PRA and ~20% by both isoforms (Kariagina et al., 2008; Sartorius 
et al., 1994). As PRB is transcriptionally more active than PRA when bound to ligand, we will 
describe the effects of PRB before PRA in this thesis. In addition, a study in a bi-inducible T47D cell 
line in which either PRB or PRA was expressed showed that, while both isoforms upregulated cell 
cycle regulator proteins and promoted proliferation, PRB also upregulated the expression of genes 
associated with DNA replication, and PRA the expression of the apoptotic marker bcl-2 (Richer et 
al., 2002). Consistent with the latter results, another study in the same cell line has shown that 
regulation of the bcl-2 gene could be mediated by PRA or a PRB:PRA heterodimer, but not by PRB 
alone (Jacobsen et al., 2002). Taken together, these studies highlight the need for investigating the 
individual roles of PRB and PRA in breast cancer.  
As already mentioned, PRA expression levels are increased relative to PRB in breast cancer (Hopp, 
2004). The importance of PRA:PRB ratios was suggested by a clinical study which showed that 
increased PRA expression relative to PRB may lead to tamoxifen resistance (Hopp, 2004). Other 
studies have suggested that tumours with increased PRA:PRB expression are of a higher tumour grade 
and respond poorly to treatment when compared to those with less PRA (Bamberger et al., 2000; 
Graham et al., 1995). In contrast to these studies, it has been shown that mice with higher PRA:PRB 
ratios are responsive to treatment with the PR antagonist, mifepristone (RU486), which mediated its 




anti-proliferative effects via PRA (Wargon et al., 2015a, 2011, 2009). The underlying mechanism for 
the success in treatment with RU486 is due to an increased interaction between the PR and a  
co-repressor at the promoters of the cyclin D1 and c-myc genes, resulting in decreased growth of 
PRA-rich tumours (Wargon et al., 2015b). However, some studies have brought into question the idea 
that PRA levels are higher than PRB levels (reviewed in Daniel et al., 2011; Knutson and Lange, 
2014). These studies suggest that the current methodologies used to measure PRB levels are 
inaccurate due to the fact that PRB is highly transcriptionally active in the breast and therefore 
undergoes rapid post-translational modification and higher rates of turnover than PRA (reviewed in 
Daniel et al., 2011; Knutson and Lange, 2014). Therefore, more data is required on the relative levels 
of the PR isoforms present in breast tumours, and new technologies are required to elucidate the 
absolute levels of PRB relative to PRA.  
Studies examining PR expression levels in prostate cancer are scarce and, as observed in breast 
cancer, do not often discriminate between PRB and PRA. Some studies have indicated that little or 
no PR mRNA is present in the normal prostatic epithelium (Hiramatsu et al., 1996; Yu et al., 2015, 
2013), while others have shown that both PRB and PRA mRNA are present (Brolin et al., 1992; Latil 
et al., 2001; Luetjens et al., 2006; Nowakowska et al., 2016). Interestingly, both PRB and PRA mRNA 
have also been reported in prostate cancer (Luetjens et al., 2006). While some studies have indicated 
that PR mRNA expression is decreased in prostate cancer and CRPC when compared to the normal 
prostate (Hiramatsu et al., 1996; Yu et al., 2015, 2013), other studies have shown that it is increased 
when compared to normal or benign prostatic hyperplasia tissue (Brolin et al., 1992; Latil et al., 2001; 
Luetjens et al., 2006; Nowakowska et al., 2016). High PR expression levels have been correlated with 
tumour progression and expression of the proliferation marker Ki67 (Bonkhoff et al., 2001; Grindstad 
et al., 2015), suggesting that the PR promotes proliferation in prostate cancer. In summary, although 
the data from the limited studies investigating PR expression levels in the prostate are contradictory, 
most of the available studies suggest that PR expression may be a poor prognostic factor in prostate 
cancer. 
To the best of our knowledge, only five studies have examined the mechanistic role of the PR in 
prostate cancer (Yu et al., 2013, 2014, 2015; Detchokul et al., 2015; Nowakowska et al., 2016). 
Interestingly, three mechanistic studies by the same research group have shown that the unliganded 
PR isoforms decrease cell migration and invasion of androgen-independent and androgen-dependent 
prostate cancer cell lines, and promote differentiation of prostate stromal cells (Yu et al., 2013, 2014, 
2015). In addition, Yu et al. (2013) showed that PRA and PRB regulated different genes in the 
presence of P4. PRA influenced the expression of genes involved in angiogenesis, while PRB 
modulated genes involved in cell cycle progression (Yu et al., 2013). Collectively the studies by Yu 




and co-workers suggest that the PR may decrease prostate cancer tumorigenesis (Yu et al., 2013, 
2014, 2015) which is in contrast to clinical studies showing that high PR expression is associated with 
prostate cancer tumour progression and clinical failure (Bonkhoff et al., 2001; Grindstad et al., 2015). 
In support of these clinical findings, however, some mechanistic studies suggest an oncogenic role 
for the PR in prostate cancer. For example, a study investigating an LNCaP model which no longer 
responds to androgens (androgen-independent) and clinical samples of patients with CRPC has 
implicated the PR as a possible mediator of resistance to treatment (Detchokul et al., 2015). This 
study showed that PR expression and activity was significantly upregulated when compared to all 
other transcription factors in response to DHT, and that oncogenesis was maintained by the regulation 
of various AR-target genes. These results suggest that the PR may be mimicking the AR by regulating 
the expression of these AR-target genes. Interestingly, Nowakowska et al. (2016) have shown that 
PR mRNA expression is increased in an LNCaP95 cell line resistant to abiraterone acetate and 
enzalutamide when compared to non-resistant cell lines. A similar increase in PR expression was 
observed upon AR knockdown in wild-type LNCaP cells (Nowakowska et al., 2016), suggesting that 
the AR regulates PR expression in prostate cancer, and that in the absence of AR signalling, the PR 
may mediate resistance to abiraterone acetate or enzalutamide. Interestingly, the GR has previously 
been shown to mediate resistance to enzalutamide by a similar mechanism in the LNCaP cell line 
(Arora et al., 2013). Moreover, it has been suggested that the AR inhibitor, ailanthone, may provide 
a mechanism to overcome enzalutamide resistance in various prostate cancer cell lines due to its 
ability to also inhibit PR activity (He et al., 2016). 
In summary, while the limited evidence regarding the role of the PR in prostate cancer is 
contradictory, the available studies have provided impetus for the investigation of the PR isoforms as 
a potential target in prostate cancer and CRPC (Bonkhoff et al., 2001; Detchokul et al., 2015; 
Grindstad et al., 2015; Nowakowska et al., 2016). 
1.3.3.1 Targeting the PR in breast and prostate cancer 
Studies targeting the PR in breast cancer using selective PR modulators (SPRMs) or PR antagonists 
have shown contradictory results. For example, studies have indicated that the PR antagonists, 
lonaprisan and telapristone acetate, as well as various SPRMs, namely EC312, EC313 and  
CDB-4124, may oppose progestogen-mediated effects by decreasing the expression of the anti-
apoptotic gene, bcl-2, inhibiting colony formation of T47D cells, and decreasing the number of  
PR-positive tumours in rats (Busia et al., 2011; Wiehle et al., 2011; Nickisch et al., 2013; Lee et al., 
2016; Nair et al., 2016). In contrast to these studies, the PR antagonist ulipristal acetate has been 
shown to increase the proliferation of the T47D cell line (Communal et al., 2012).  




Clinical trials investigating PR ligands in breast cancer therapies have had limited success due to 
structural similarities between the PR, AR and GR (Meyer et al., 1990; Wagner et al., 1996; Leonhardt 
and Edwards, 2002). For example, a trial investigating the use of the PR antagonist, RU486, and the 
SPRM, onapristone, for the treatment of post-menopausal breast cancer showed that patients did not 
effectively respond to therapy, and that significant liver toxicity was observed (Perrault et al., 1996; 
Han et al., 2007; Jonat et al., 2013). Although another study showed that the SPRM, onapristone, was 
effective in decreasing tumour size in patients, the trial was ended due to patients exhibiting 
hepatoxicity (Robertson et al., 1999). It is important to note that the effects of SPRMs or PR 
antagonists may not be PR-specific (Andrieu et al., 2015), thus future studies should investigate the 
effects of these drugs on both GR- and AR-mediated action prior to clinical testing. 
To the best of our knowledge, two clinical trials are currently investigating the PR as a target in 
prostate cancer (Trial number: NCT02049190) (Jayaram and Nowakowska, 2015). While one trial is 
investigating the use of onapristone in combination with abiraterone acetate to treat advanced CRPC 
and metastatic CRPC (Trial number: NCT02049190) (reviewed in Antonarakis et al., 2016), the other 
trial is examining the use of onapristone before administration of either abiraterone acetate or 
enzalutamide in CRPC patients (Jayaram and Nowakowska, 2015). Preliminary results from the latter 
trial indicate that onapristone effectively abrogates PR expression with minimal toxicity (Jayaram 
and Nowakowska, 2015). However, whether onapristone results in any significant clinical benefits in 
CRPC patients has yet to be determined, and the likelihood that it will have cross-reactivity with the 
GR in prostate cancer patients, as observed in breast cancer patients, cannot be excluded (Robertson 
et al., 1999). 
1.3.4  Crosstalk between the ER, AR and PR in breast and prostate cancer 
1.3.4.1 ER-AR crosstalk 
A number of studies have investigated crosstalk between ERα and the AR in breast cancer (Kumar et 
al., 1994; Panet-Raymond et al., 2000; Peters et al., 2009; D’Amato et al., 2016), with several studies 
indicating that the activity of ERα is inhibited by the AR (Kumar et al., 1994; Panet-Raymond et al., 
2000; Peters et al., 2009; D’Amato et al., 2016). The mechanism for this inhibition has been attributed 
to the AR competing with ERα for binding to EREs (Peters et al., 2009) or by the AR increasing the 
expression of ERβ (Rizza et al., 2014). Indeed, it has been shown that the AR can decrease  
ERα-mediated activation of the ERE-containing pS2 gene (Panet-Raymond et al., 2000) and the  
ERE-containing PR gene (Peters et al., 2009). In contrast, other studies have suggested that the AR 
may in fact be required for optimal E2-mediated oncogenicity in ERα-positive breast cancer cells. For 
example, a study in the MCF-7 breast cancer cell line has suggested that a functional AR is required 




for an optimal response to E2 (Cochrane et al., 2014), while another study has shown that treatment 
with E2 redirects AR binding sites such that the AR primarily recognises ERE sequences (D’Amato 
et al., 2016). These studies suggest that the AR may be a poor prognostic factor in ER-positive breast 
cancer. 
Conversely, it has been shown that liganded ERα decreased AR-mediated activation on an ARE 
(Kumar et al., 1994; Panet-Raymond et al., 2000) via a direct interaction between these receptors 
(Panet-Raymond et al., 2000). Although this study reported that the AR and ERβ do not directly 
interact (Panet-Raymond et al., 2000), a study from our laboratory has previously shown that the 
liganded AR inhibits the transrepression, but not transactivation, function of ERβ via an ERE (Easter 
Ndlovu, MSc thesis). As mentioned earlier, it has been shown that the activated AR can increase ERβ 
gene expression in the MCF-7 and ZR751 breast cancer cell lines by binding to an ARE sequence in 
the ERβ promoter region (Rizza et al., 2014). The increased ERβ resulted in decreased cell 
proliferation (Rizza et al., 2014), which may be due to ERβ limiting ERα-mediated proliferation.  
To the best of our knowledge, no studies have investigated crosstalk between the AR and ERα in 
prostate cancer, while at least two studies have investigated AR-ERβ crosstalk (Muthusamy et al., 
2011; Grubisha and DeFranco, 2013). Interestingly, both these studies showed that ERβ, when 
activated by either androgen metabolites (Grubisha and DeFranco, 2013), or estrogenic metabolites 
of DHT (Muthusamy et al., 2011), opposes AR-mediated prostate cancer cell proliferation.  
In summary, the data suggest that significant crosstalk exists between ERα and the AR in breast 
cancer, which may explain the divergent role of the AR in ERα-positive versus ERα-negative breast 
cancers. In contrast, crosstalk between the AR and ERβ in breast cancer is less well investigated, 
while it appears to have an important role in prostate cancer. Finally, unlike the numerous studies 
examining the interaction between the AR and ERα in breast cancer, not much is known about the 
interplay between these receptors in prostate cancer. 
1.3.4.2 ER-PR crosstalk 
Several studies have investigated crosstalk between ERα and the PR in breast cancer (Giulianelli et 
al., 2012; Daniel et al., 2015; Mohammed et al., 2015; Singhal et al., 2016). For example, it has been 
shown that, even though MPA does not bind to the ER subtypes, ERα is required for the PR-mediated 
effects of MPA on breast cancer cell proliferation (Giulianelli et al., 2012). This study also showed 
that ERα and the PR are co-recruited to the promoters of the oncogenes, cyclin D1 and c-myc, thereby 
increasing their expression (Giulianelli et al., 2012). In addition, both PR isoforms could interact with 
ERα in the nuclei of human MPA-treated cells. Another study has shown that unliganded PRB 




enhances ERα-regulated gene expression and breast cancer cell proliferation (Daniel et al., 2015). In 
contrast to the above-mentioned studies indicating that crosstalk between ERα and the PR are 
associated with poor prognosis in breast cancer, two recent studies suggest that it is associated with 
a good prognosis when the PR is activated (Mohammed et al., 2015; Singhal et al., 2016). For 
example, Mohammed and co-workers showed that PR activated by P4 or the synthetic progestin 
promegestone (R5020), redirects ERα to new chromatin binding sites, thereby inhibiting  
ERα-mediated oncogenic effects (Mohammed et al., 2015; Singhal et al., 2016). A more indirect 
mechanism of crosstalk has been shown between ERα and PRB in the T47D cell line treated with 
R5020 (Migliaccio et al., 1998; Ballare et al., 2003). Specifically, it has been shown that  
PRB-mediated activation of a proliferation-promoting kinase pathway was dependent on the presence 
of ERα, and prevented by both PR and ER antagonists (Migliaccio et al., 1998; Ballare et al., 2003). 
Whether crosstalk between ERα and the PR in breast cancer is associated with poor or good prognosis 
thus appears to be largely dependent on the presence and type of ligand used to activate the PR. 
Moreover, whether similar crosstalk mechanisms exist between ERβ and the PR is not known. 
Finally, similar crosstalk mechanisms between the ER subtypes and the PR has to the best of our 
knowledge, not been investigated in prostate cancer. 
1.3.4.3 PR-AR crosstalk 
To the best of our knowledge, no study has directly investigated crosstalk between the PR and AR in 
breast or prostate cancer. However, possible PR-AR crosstalk may be inferred from the available 
data. Members of the KLK serine protease family are known to be regulated by steroids in breast and 
prostate cancer (Nelson et al., 1999; Lai et al., 2009), and the PSA protein is transcribed from the 
AR-regulated KLK3 gene (Nelson et al., 1999; Lai et al., 2009). Most KLK proteins are responsible 
for cleaving proteins involved in invasion and metastasis (Clements et al., 2004; Paliouras et al., 
2007). A study by Lai et al. (2009) investigated the regulation of KLK4 gene expression in the T47D 
breast and LNCaP prostate cancer cell lines, and found that the KLK4 gene was expressed only in the 
presence of the PR and AR in breast and prostate cancer cells, respectively. Notably, while this study 
did not investigate whether the AR was expressed in the T47D cell line or PR expression in the 
LNCaP cell line, it is known that these receptors are endogenously expressed in these cell lines 
(Horwitz et al., 2008; Detchokul et al., 2015). This is significant since the KLK4 gene promoter, like 
the PSA gene, contains both a PRE and selective ARE sequence (Nelson et al., 1999; Lai et al., 2009), 
and it is known that both the AR and PR can regulate the expression of genes via a PRE/classical 
ARE (Beato, 1989). Lai and co-workers found that P4 upregulated KLK4 gene expression via the PR 
binding to the PRE in the T47D cell line. In the LNCaP cell line, however, the data was less 
straightforward. Although the synthetic androgen R1881 induced both KLK4 and PSA gene 




expression, treatment with bicalutamide only partially abrogated the expression of both genes. 
Although these results suggest that the AR is not the only steroid receptor mediating these effects, 
the authors concluded that the effects on PSA, but not KLK4, gene expression were AR-mediated. 
Furthermore, the study revealed that the AR DBD was not binding directly to the KLK4 selective 
ARE, and that the KLK4 promoter lacking the PRE sequence could not be activated by R1881, leading 
the authors to suggest that the AR regulates KLK4 gene expression by tethering to AR co-regulators. 
An oversight by this study was the fact that the authors did not consider that KLK4 gene expression 
in the LNCaP cell line may be mediated by the AR binding to the PRE sequence, as it is known that 
the AR can bind to a PRE/classical ARE sequence (Dubé et al., 1976; Cowan et al., 1977; Lai et al., 
2009). Moreover, the authors did not consider the fact that R1881 is known to bind the PR with high 
affinity (Dubé et al., 1976; Cowan et al., 1977). Thus, it is possible that the PR alone, or both the PR 
and AR may be mediating the activation of the putative AR-regulated KLK4 gene in the LNCaP cell 
line via the PRE. In addition, some studies have also implicated crosstalk between androgen and 
progesterone signalling pathways in prostate cancer. For example, resistance to abiraterone acetate in 
prostate cancer has been linked to an AR mutant (T878A) which is more responsive to P4. This  
P4-induced mutant AR was shown to activate the expression of various AR-target genes (Chen et al., 
2015). However, this study did not investigate the possibility that P4 may be mediating these actions 
via the PR, and not the AR, which is likely since P4 is a potent PR agonist (Khan et al., 2013) that is 
known to display AR antagonist activity (Africander et al., 2014). Furthermore, recent evidence 
suggests that P4 levels are significantly upregulated in patients undergoing treatment with abiraterone 
acetate or enzalutamide (McKay et al., 2017; Montgomery et al., 2017), which is of concern since 
high PR expression levels are also present in prostate cancer and CRPC patients. 
More evidence implicating a potential role for PR-AR crosstalk in prostate cancer arises from a study 
investigating the role of the GR, which is structurally homologous to both the PR and AR (Gao et al., 
2005). As mentioned earlier, the PR, AR and GR recognise the same hormone response element 
sequence. This sequence is termed the PRE when the PR is bound, the classical ARE when the AR is 
bound, or the glucocorticoid response element (GRE) when the GR is bound (Beato, 1989). Arora 
and co-workers showed that the GR was able to confer resistance to enzalutamide by binding to and 
activating selective AREs (Arora et al., 2013). The GR was able to directly modulate the expression 
of various AR-target genes and it was found that more than 80% of AR- or GR-regulated genes were 
modulated by the reciprocal receptor. Importantly, the authors state that the restoration of androgen 
signalling cannot solely be explained by the actions of the GR, as 43% of AR target genes containing 
GR binding sites within their promoters were not modulated by the GR. This suggests that another 
steroid receptor may be involved in mediating resistance to enzalutamide. As the AR and PR share 




88% overall sequence homology, and the PR is known to be associated with tumour progression and 
resistance to treatment in prostate cancer (Marhefka et al., 2001), it is highly likely that the PR may 
be also be involved in conferring resistance to enzalutamide.  
 Conclusion 
A multitude of similarities exist between breast and prostate cancer. While the role of the AR in 
prostate cancer is well defined, its role in breast cancer seems to be dependent on the expression of 
the ER. Although the AR may be protective in ER-positive breast cancer (Peters et al., 2009), studies 
have shown that the AR may be pro-tumorigenic in ER-negative breast cancer via a mechanism 
involving binding of the AR to EREs (Peters et al., 2009; Cochrane et al., 2014). The role of other 
steroid receptors such as the PR have been largely neglected in breast and prostate cancers. However, 
several studies have begun to address this in breast cancer, while similar studies in prostate cancer 
are limited. While the PR seems to be a negative or positive prognostic factor in breast cancer 
depending on whether it is unliganded or liganded, as well as the nature of the ligand bound (Hopp, 
2004; Mote et al., 2015), the PR appears to be a poor prognostic factor in prostate cancer (Bonkhoff 
et al., 2001; Grindstad et al., 2015). Since it is known that the AR can bind to EREs in the promoter 
of the PR gene, and that others have shown that AR inhibition decreases PR expression in breast 
cancer and prostate cancer (Peters et al., 2009; Nowakowska et al., 2016; Wellberg et al., 2017), it is 
likely that the AR may regulate PR expression in both cancers. Thus, it is likely that the AR and PR 
are co-expressed in a subset of breast and prostate cancers. As crosstalk between the AR and ER 
(Panet-Raymond et al., 2000; Peters et al., 2009; Rizza et al., 2014), as well as between ERα and PR 
(Mohammed et al., 2015) has been shown in breast cancer, it raises the question whether similar 
crosstalk mechanisms exist in prostate cancer. Interestingly, crosstalk between the GR and AR has 
been shown in prostate cancer, where the GR mimics AR activity by regulating AR-target genes. 
Considering that the PR, AR and GR are structurally homologous and recognise the same DNA 
sequences, it is likely that the PR may also mimic AR activity. Taken together, the available evidence 
suggests that an interplay between the AR and the PR may be possible. Understanding crosstalk 
mechanisms in breast and prostate cancer is imperative to our understanding of the role of steroid 
receptors as mediators of breast and prostate development and progression, and may aid in the 








 Aims of the study 
Evidence in the literature suggests that the AR and PR are co-expressed in a subset of both breast and 
prostate cancer tumours and that PR expression is upregulated in both cancers. Given that crosstalk 
between steroid receptors plays an integral role in breast cancer, and that overlapping mechanisms 
exist between breast and prostate cancer, the main aim of this study was to investigate the effects of 
PR isoforms on AR-mediated transactivation in breast and prostate cancer cell lines. As the AR is 
known to transactivate via the classical ARE/PRE, selective ARE and ERE, while the PR is only 
known to transactivate via the PRE/classical ARE, AR-mediated transactivation was investigated on 
all of these response elements. The AR- and PR-negative MDA-MB-231 and PC3 cell lines were 
employed as in vitro models of breast and prostate cancer, respectively.  
The specific aims were as follows: 
1. To validate the proposed experimental system. 
2. To evaluate the effect of increasing concentrations of PRB or PRA, in the absence of PR 
ligands, on the transactivation function of the AR via the PRE/classical ARE, selective ARE 
and ERE. 
3. To determine the effect of increasing concentrations of PRB or PRA, in the presence of PR 
ligands, on the transactivation function of the AR via the PRE/classical ARE, selective ARE 
and ERE. 
4. To elucidate whether PRB and PRA, like the AR, can transactivate via the selective ARE and 
ERE. 
5. To determine whether PRB or PRA, in the absence and presence of PR ligands, would 




























The test compounds used in this study included the natural androgen 5α-androstan-17β-ol-3-one (5α-
dihydrotestosterone; DHT), the synthetic androgen 7α,17α-dimethyl-19-nortestosterone (mibolerone; 
Mib), the natural progestogen 4-pregnene-3,20-dione (progesterone; P4); the progestins  
17,21-dimethyl-19-nor-4,9-pregnadiene-3,20-dione (promegestone; R5020) and 17α-hydroxy-6α-
methyl-4-pregene-3,20-dione 17-aceate (medroxyprogesterone acetate; MPA). All the test 
compounds were obtained from Sigma-Aldrich, South Africa, prepared in absolute ethanol (EtOH) 
and stored at -20°C. For promoter-reporter studies, the compounds were added to serum- and phenol 
red-free Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 3.5 g/L glucose (Sigma-
Aldrich, South Africa). For proliferation studies, the compounds were added to phenol red-free 
DMEM supplemented with 3.5 g/L glucose (Sigma-Aldrich, South Africa), 10% charcoal-stripped 
(Addendum A) fetal calf serum (CS-FCS) and 100 IU/mL penicillin and 100 μg/mL streptomycin 
(1% penicillin/streptomycin) (Sigma-Aldrich, South Africa). Compounds were diluted such that a 
final EtOH concentration of 0.2% v/v was obtained, thus 0.2% v/v EtOH was used for control 
incubations (without test compounds), and will hence be referred to as the vehicle control. 
 Plasmid DNA 
2.2.1  Expression vectors 
The cDNA expression vectors for human PRA (pSG5-hPR-A) and PRB (pSG5-hPR-B) were a kind 
gift from Prof. E. Kalkhoven (Utrecht University Medical Centre, Netherlands) (Wissink and 
Kalkhoven, 1996), while the empty pSG5 expression vector was kindly provided by Prof. G. Mellgren 
(University of Bergen, Norway). The pTAT-PRE-E1b-luc promoter-reporter construct driven by the 
E1b promoter and containing two copies of the TAT-PRE was obtained from Prof. G. Jenster 
(Erasmus University of Rotterdam, Netherlands) (Jenster et al., 1997), while the human AR cDNA 
expression vector (pSG5-hAR) was provided by Prof. H. Klocker (Medical University of Innsbruck, 
Austria) (Shatkina et al., 2003). The previously described selective ARE luciferase promoter-reporter 
construct, 4xSC-ARE1.2, was a kind gift from Prof. F. Claessens (University of Leuven, Belgium) 
(Verrijdt et al., 1999). Plasmids expressing human ERα (pSG5-ERα) and human ERβ (pSG5-ERβ) 
were obtained from Prof. F. Gannon (European Molecular Biology Laboratory, Germany) (Flouriot 
et al., 2000), while the 2xERE-pS2-pGL3 luciferase promoter-reporter construct containing two 
copies of the ERE was obtained from Prof. B. Belandia (Institute for Biomedical Research, Spain) 
(Belandia and Parker, 2000). The cDNA expression vectors expressing human mineralocorticoid 




receptor (pRS-hMR) and human GR (pRS-hGR) were kind gifts from Prof. R. Evans (Howard 
Hughes Medical Institute, USA) (Arriza et al., 1987). 
 Preparation and transformation of competent bacterial cells 
Escherichia coli (E. coli) DH5α cells were made competent using the calcium chloride method and 
transformed using the heat shock method (Sambrook et al., 1989). Briefly, a single colony of the  
E. coli DH5α cells were inoculated into 25 mL Luria Bertani (LB) broth (Addendum A), and grown 
for 6 hours at 300 rpm at 37ºC. The cells were subsequently exposed to a cold-shock on ice for  
10 minutes before collecting the cell pellet by centrifugation at 6000 rpm for 3 minutes in the Avanti® 
J-E centrifuge (Beckman Coulter Inc., USA). The cell pellet was resuspended in 10 mL cold  
0.1 M CaCl2 solution and incubated on ice for 20 minutes before centrifugation as described above. 
Finally, the cells were resuspended in 5 mL cold 0.1 M CaCl2 containing 15% glycerol and stored at 
-80ºC until needed. For the transformation, 100 µL of the competent cells were thawed on ice for  
10 minutes and 100 ng plasmid DNA added (Tang et al., 1994; Froger and Hall, 2007). Following an 
incubation on ice for 30 minutes, the cell/DNA solution was exposed to a 30 second heat shock at 
42ºC and incubated on ice for 5 minutes. The cells transformed with the desired plasmids were 
subsequently grown in super optimal broth medium with catabolite repression (SOC) (Addendum A) 
at 37ºC for 1 hour at 300 rpm. The streak-plate method was used to plate the transformed cells onto 
agar plates containing 50 µg/mL ampicillin, and incubated at 37ºC for 16 hours. Ampicillin was used 
since all the plasmids used in this study contain an ampicillin-resistance gene. 
2.3.1  Plasmid DNA extraction 
Plasmid DNA was extracted using the NucleoBond® Xtra Maxi Plasmid Preparation kit (Macherey-
Nagel, USA) as per the manufacturer’s instructions. Briefly, a starter culture of the transformed cells 
was prepared by inoculating a single colony into 5 mL LB broth containing 50 µg/mL ampicillin for 
selection, followed by an incubation at 37ºC for 8 hours at 300 rpm. Thereafter, 5 mL of the starter 
culture was added to 250 mL LB broth and incubated at 37ºC for 16 hours at 300 rpm to allow the 
cells to reach the exponential growth phase. The cell pellet was collected by centrifugation at  
6000 x g for 10 minutes at 4ºC. The All reagents used were provided in the NucleoBond® Xtra Maxi 
Plasmid Preparation kit (Macherey-Nagel, USA), unless otherwise specified. Briefly, the bacterial 
cells were resuspended in lysis buffer using an optimised NaOH/sodium dodecyl sulfate (SDS) lysis 
method (Birnboim and Doly, 1979). After equilibration of the anion-exchange chromatography 
column, the lysate was loaded onto the column and cleared by gravitational flow. Following several 




wash steps, the plasmid DNA bound to the column was eluted, then precipitated, and dissolved in 
Tris-EDTA (TE) buffer (Addendum A).  
2.3.2  Restriction enzyme digest and agarose gel electrophoresis 
To confirm the integrity and size of the extracted plasmid DNA, the undigested DNA and restriction 
enzyme digests of the DNA were separated on a 1% agarose gel by electrophoresis at 100 V 
(Addendum B, Fig. S1). Briefly, the plasmid DNA concentrations, measured in ng/µL, were obtained 
using a NanoDrop™ MicroVolume spectrophotometer (ThermoFisher Scientific, South Africa) 
which was available at the Stellenbosch University Central Analytical Facility (CAF). For digestion 
of the plasmids, 200 ng of the plasmid DNA was incubated with 0.2 U of the specific enzyme and an 
appropriate concentration of the respective enzyme buffer at 37ºC for 1 hour. The undigested and 
digested plasmid DNA were diluted to a final concentration of 10 ng/µL using 6x orange DNA 
loading dye (ThermoFisher Scientific, South Africa), and loaded onto the agarose gel prior to 
electrophoresis. 
 Cell culture 
The MDA-MB-231 human breast adenocarcinoma cell line was a kind gift from Prof. A. Edkins 
(Rhodes University, South Africa), while the COS-1 monkey kidney and HEK293 human embryonic 
kidney cells were obtained from the American Type Culture Collection (ATCC, USA). All the above-
mentioned cell lines were maintained in DMEM containing phenol red and 4.5 g/L glucose (Sigma-
Aldrich, South Africa) supplemented with 10% fetal calf serum (FCS) (The Scientific Group, South 
Africa) and 1% penicillin/streptomycin (Sigma-Aldrich, South Africa). The MDA-MB-231 cell line 
was additionally supplemented with 2 mM L-glutamine (Sigma-Aldrich, South Africa), and this 
medium will hence be referred to as complete DMEM for this cell line. The PC3 human prostate 
carcinoma cell line was kindly provided by Prof. A. Swart (Stellenbosch University, South Africa). 
These cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium containing 
4.5 g/L glucose (Sigma-Aldrich, South Africa) supplemented with 10% FCS (The Scientific Group, 
South Africa) and 1% penicillin/streptomycin (Sigma-Aldrich, South Africa), and will hence be 
referred to as complete RPMI medium for this cell line. All cell lines were maintained in 75 cm2 
culture flasks (Bio-Smart Scientific, South Africa) at 37ºC in an atmosphere of 90% humidity and 
5% CO2, and sub-cultivated with 2 mL 0.25% (w/v) trypsin-0.53 mM EDTA solution (Sigma Aldrich, 
South Africa) when the cells reached 80-90% confluency. The cell lines were regularly tested for 
mycoplasma infection using the Hoechst staining technique (Freshney, 2010) and only mycoplasma 
negative cell lines were used for experiments (Addendum B, Fig. S2). All experiments were 




conducted within the first 25 to 30 passages after thawing of the MDA-MB-231 and PC3 cell lines, 
respectively.  
 Luciferase promoter-reporter assays  
The MDA-MB-231 and PC3 cell lines were maintained as described in Section 2.4 and seeded into  
6 cm dishes at a density of 0.8x106 cells per dish in complete DMEM or RPMI medium, respectively. 
The next day, the cells were transiently transfected with 300 ng of either the empty vector (pSG5) or 
the expression vector for the human AR (pSG5-hAR) and 3000 ng of the promoter-reporter construct 
containing either the PRE (pTAT-PRE-E1b-luc), selective ARE (4xSC-ARE1.2) or ERE (2xERE-
pS2-pGL3) sequence, in the absence and presence of 300 or 1500 ng of the expression vector(s) for 
PRA (pSG5-hPR-A) or PRB (pSG5-hPR-B). XtremeGENE HP DNA transfection reagent (Sigma-
Aldrich, South Africa) was used for transfections as per the manufacturer’s instructions. The pSG5 
empty vector was used as a filler plasmid to ensure a constant amount of 4800 ng total DNA in all 
experiments, and to confirm that responses observed with ligand in the presence of transiently 
transfected steroid receptor were due to the transfected steroid receptor. After a 24 hour incubation 
period, the transiently transfected cells were seeded into 96-well plates at a density of 1x104 cells per 
well (Fig. 2.1) using phenol red-free DMEM supplemented with 3.5 g/L glucose (Sigma-Aldrich, 
South Africa), 10% CS-FCS and 1% penicillin/streptomycin (Sigma-Aldrich, South Africa) and 
allowed to settle. The following day, the cells were treated for 24 hours with either the vehicle control 
or 1 nM ligand(s) prepared in serum- and phenol red-free DMEM supplemented with 3.5 g/L glucose. 
Following the incubation period, the cells were washed with 200 μL phosphate-buffered saline (PBS) 
solution, lysed with 25 μL passive lysis buffer (Addendum A) and stored at -20°C. The cell lysates 
were thawed and 5 µL used to measure the luciferase activity in relative light units (RLU) using the 
Promega luciferase assay system (Promega, USA) and the Veritas microplate luminometer (Turner 
Biosystems, USA). RLU values were normalised to the total protein concentration (mg/mL) of each 
lysate, determined using the Bradford protein assay method (Bradford, 1976). The data is represented 
as fold induction with the vehicle control is set as 1 and all other responses set relative to this. In 
experiments where the PR and AR are co-expressed, the fold induction of the AR in the presence of 
DHT is set as 100%, while responses obtained in the presence of the PR isoforms is expressed relative 
to that of the AR alone.  







Figure 2.1: Illustration of the experimental layout for promoter-reporter, cell proliferation and western blot 
assays. MDA-MB-231 or PC3 cells were seeded into 6 cm dishes at 0.8x106 cells per dish in complete DMEM or RPMI 
medium, respectively. The cells were subsequently transiently transfected with the appropriate expression vectors and 
incubated for 24 hours before seeding into either 96-well plates at 1x104 cells per well for promoter-reporter or  
2x103 cells per well for cell proliferation assays, or 24-well plates at 5x104 cells per well for western blot analysis. 
 Western blot analysis 
2.6.1  Preparation of protein lysates 
To observe changes in AR, PRA, and PRB expression levels upon transfection, the MDA-MB-231 
and PC3 cells were seeded into 24-well plates at a cell density of 5x104 cells per well in phenol  
red-free DMEM supplemented with 3.5 g/L glucose (Sigma-Aldrich, South Africa), 10% CS-FCS 
and 1% penicillin/streptomycin (Sigma-Aldrich, South Africa) (Fig. 2.1). The following day, the cells 
were treated with the vehicle control which was prepared in serum- and phenol red-free DMEM 
supplemented with 3.5 g/L glucose (Sigma-Aldrich, South Africa), and incubated for a further  
24 hours. Thereafter, the cells were rinsed with 500 µL PBS per well before lysis with 100 μL passive 
lysis buffer (Addendum A). To pellet the cell debris, the samples were centrifuged for 10 minutes at 
12 000 x g at 4°C, and the protein lysate transferred to a sterile tube. Protein concentrations of the 
samples were determined using the Bradford protein determination method (Bradford, 1976). The 
amount of 2x Laemmli SDS-sample buffer that was added to the samples varied depending on the 
protein concentration.  




To characterise the endogenous steroid receptor expression of the MDA-MB-231 and PC3 cell lines, 
these cells were maintained as described in Section 2.4 and seeded into 6-well plates at a density of 
2.5x105 cells per well and incubated until cells reached confluency. Positive controls were prepared 
by maintaining COS-1 and HEK293 cells as described in Section 2.4 and seeding these cells into  
12-well plates at a density of 1x105 cells per well. The COS-1 cells were transiently transfected with 
250 ng of an expression vector encoding either the AR, ERα, ERβ or GR, while the HEK293 cells 
were similarly transiently transfected with PRA or PRB, using the XtremeGENE HP DNA 
transfection reagent (Sigma-Aldrich, South Africa) as per the manufacturer’s instructions. Negative 
controls were prepared by seeding untransfected COS-1 cells into 12-well plates at a density of  
1x105 cells per well. All cells were grown until confluency was reached, washed with PBS solution 
and then lysed with 80 μL of 2x Laemmli SDS-sample buffer (Addendum A).  
2.6.2  SDS-PAGE and western blot analysis 
Cell lysates were denatured by boiling at 95°C for 10 minutes. The proteins were separated on a  
10% SDS-polyacrylamide gel at 100 V for 15 minutes, followed by 200 V for 1 hour in SDS-PAGE 
running buffer (Addendum A). The broad-range Color Prestained Protein ladder was used as a 
reference standard (New England BioLabs Inc., USA). The separated proteins were transferred onto 
nitrocellulose membranes (AEC Amersham, South Africa) in ice-cold transfer buffer (Addendum A) 
using the BioRad transfer unit (Bio-Rad, South Africa) for 1.5 hours at 180 mA. Thereafter, the 
nitrocellulose membranes were blocked for 2 hours in 10% w/v fat-free milk powder prepared in  
Tris-buffered saline containing 0.1% Tween-20 (TBST) at room temperature with agitation. The 
membranes were then washed with TBST to remove residual milk proteins, and subsequently 
incubated with the appropriate primary antibody for 16 hours with agitation at 4°C. Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) was used as a loading control. Following the incubation with 
primary antibody, the membranes were washed with TBST once for 15 minutes, twice for 5 minutes, 
and once in TBS for 5 minutes. The membranes were then incubated with the relevant horseradish 
peroxidase (HRP)-conjugated secondary antibody prepared in 10% w/v fat-free milk powder in TBST 
for 1 hour at room temperature with agitation. The membranes were subsequently washed as 
described above and the proteins were visualised using the Clarity™ Western ECL Substrate  
(Bio-Rad, South Africa) and the MyECL imaging system (Thermo Fisher Scientific, South Africa). 
The images were quantified using the myImageAnalysis software version 2.0 (Thermo Fisher 
Scientific, South Africa), and specific steroid receptor protein levels were normalised to that of 
GAPDH. The details of the primary and secondary antibodies used in this study are summarised in 
Table 2.1. 





Table 2.1 Details of primary and secondary antibodies used for western blotting. 
Protein Primary antibody Dilution Secondary antibody Dilution 
AR AR-441 1:1000 Goat anti-mouse 1:3000 
ERα ERα HC-20 1:1000 Goat anti-rabbit 1:1000 
ERβ ERβ H-150* 1:500 Goat anti-rabbit 1:1000 
GR GR H-300 1:3000 Goat anti-rabbit 1:4000 
PRA/B PGR-312** 1:500 Goat anti-mouse 1:2000 
GAPDH GAPDH 0411 1:3000 Goat anti-mouse 1:2000 
All antibodies were purchased from Santa Cruz Biotechnology (USA), while antibodies purchased from 
Abcam (UK) are indicated by * and antibodies purchased from Leica Biosystems (UK) are indicated by **. 
 
 Cell proliferation assays 
The MDA-MB-231 and PC3 cell lines were maintained as described in Section 2.4 before seeding 
into 6 cm dishes at a density of 0.8x106 cells per dish in complete DMEM or RPMI medium, 
respectively. The next day, the cells were transiently transfected with 300 ng of either the empty 
vector (pSG5) or the expression vector for the human AR (pSG5-hAR), using the XtremeGENE HP 
DNA transfection reagent (Sigma-Aldrich, South Africa) as per the manufacturer’s instructions. 
Following a 24 hour incubation, the transfected cells were seeded into 96-well plates at a density of 
2x103 cells per well (Fig. 2.1) and allowed to settle. The cells were then treated for 72 hours with 
either the vehicle control or 1 nM of the relevant ligand prepared in phenol red-free DMEM 
supplemented with 3.5 g/L glucose, 10% CS-FCS and 1% penicillin/streptomycin. Following the 
incubation, new compound mixtures were prepared and the cells were re-treated for a further  
48 hours, before the addition of 50 μL of the colorimetric 3-(4,5-di dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide (MTT) reagent (Sigma-Aldrich, South Africa) and 150 μL phenol  
red-free DMEM supplemented with 10% CS-FCS and 1% penicillin/streptomycin. MTT is based on 
the principle that the yellow MTT thiazolyl solution is reduced by NADPH-dependent oxidoreductase 
enzymes present in the mitochondria of metabolically active cells to form purple, insoluble formazan 
crystals that can be solubilised and quantified spectrophotometrically. Following the 4 hour 
incubation period with MTT, the solution was aspirated and 200 μL dimethyl sulphoxide (DMSO) 




(Sigma-Aldrich, South Africa) added to solubilise the formazan crystals. The absorbance was 
measured at 540 nm using the BioTek spectrophotometer (BioTek Instruments, USA). For the alamar 
blue proliferation assay, following the initial 72 hour incubation with compounds, new compound 
mixtures were prepared and the cells were re-treated for a further 168 hours, before the addition of 
20 µL of the resazurin sodium salt (Sigma-Aldrich, South Africa) to a final concentration of  
0.15 mg/mL. The absorbance was read at 570 nm and 600 nm using the BioTek spectrophotometer 
(BioTek Instruments, USA). The alamar blue proliferation assay is a non-toxic alternative to the MTT 
assay, and is based on a similar principle in which resazurin sodium salt is reduced by active 
oxidoreductase enzymes in the mitochondria of living cells. For both the MTT and alamar blue 
proliferation assays, proliferation is shown as a fold induction obtained with the specific compound 
relative to the vehicle control set as 1. 
 Data manipulation and statistical analysis 
GraphPad Prism® version 5.00 (GraphPad Software, USA) was used for graphical representation, 
data manipulation and statistical analysis. Data was presented as means ± standard error of the mean 
(SEM) of at least two independent experiments, unless otherwise stated. Column statistics were 
applied to analyse the grouped data using one-way analysis of variance (ANOVA) and Newman 
Keul’s post-tests (to compare all columns). Statistically significant differences are indicated  
by * (p<0.05), ** (p<0.01) or *** (p<0.001). No statistical difference is indicated by ns where p>0.05. 
 
























3.1  Confirmation that MDA-MB-231 and PC3 cell lines do not express AR or PR 
The MDA-MB-231 breast adenocarcinoma and the PC3 prostate adenocarcinoma cell lines were 
identified as model cell lines for this study, as they have both been reported to lack AR and PR 
expression (Sasaki et al., 2002; Terakawa et al., 2010; Holliday and Speirs, 2011; Narayanan et al., 
2014). To confirm the absence of these steroid receptors, and investigate whether any other steroid 
receptors are expressed in the MDA-MB-231 and PC3 cell lines, we characterised endogenous steroid 
receptor expression by performing western blot analysis with lysates of the cell lines. The results in 
figure 3.1 indicate that only the GR is expressed in the MDA-MB-231 cell line, while only ERα is 
expressed in the PC3 cell line. Notably, the commercial antibody used to detect ERβ was not optimal 
as detection of ERβ in the positive control showed minimal expression of ERβ. Thus, we cannot 
definitively say whether or not the MDA-MB-231 and PC3 cell lines express endogenous ERβ.  
 
Figure 3.1: Characterising the endogenous steroid receptor expression in MDA-MB-231 breast cancer and PC3 
prostate cancer cell lines. Whole cell extracts were prepared from the MDA-MB-231 and PC3 cell lines, and protein 
lysates analysed by western blotting using antibodies specific to the AR, PRA, PRB, GR, ERα, ERβ, or GAPDH (loading 
control). Protein lysates from COS-1 cells transfected with expression vectors encoding either the AR, GR, ERα or ERβ, 
or HEK293 cells transfected with expression vectors for either PRA or PRB were used as positive controls (+). 








3.2  The transcriptional activity of PRB and the AR was confirmed on selected 
response elements 
Given that we had confirmed that neither the MDA-MB-231 breast cancer nor PC3 prostate cancer 
cell lines express endogenous AR, PRA or PRB, these cell lines were employed to investigate the 
transcriptional activity of overexpressed AR and/or PRB on specific steroid response elements. PRB 
was used to validate the PRE as it is known to be more transcriptionally active than PRA in the 
presence of ligand (Kariagina et al., 2008). Since the DBD of steroid receptors is highly conserved, 
most steroid receptors can bind the same DNA response element (Gao et al., 2005). Thus, while PR 
isoforms can transactivate via a PRE, the AR, GR and MR can also recognize this response element. 
We thus used the PRE as a response element for PRB, but also as a response element for the AR 
(herein referred to as a classical ARE). Although the PRE/classical ARE and the response element 
for the ER, namely the ERE, are highly dissimilar, an ERE was also employed as Peters et al. (2009) 
had previously shown that the AR could bind to this response element. In addition, a previously 
described response element via which the AR but not the GR could transactivate, called an  
AR-selective ARE, was also used (Verrijdt et al., 1999). Thus, we wanted to validate the luciferase 
promoter-reporter assay in the MDA-MB-231 and PC3 cell lines using luciferase promoter-reporter 
constructs containing the PRE/classical ARE, selective ARE and ERE.  
MDA-MB-231 breast cancer and PC3 prostate cancer cell lines were thus transiently transfected with 
either an empty vector (indicated throughout by grey bars) or PRB (indicated throughout by blue 
bars) together with the PRE luciferase (PRE-luc) promoter-reporter construct, and the cells treated 
with various progestogens (natural and synthetic PR ligands) (Fig. 3.2 A-B). Specifically, we used 
the classical potent synthetic progestin, R5020, a so-called PR-specific agonist, the natural PR ligand, 
P4, and MPA, a synthetic PR ligand used clinically in HT and contraception in women, and which 
has also been investigated as a potential male contraceptive (Bain et al., 1980; Doody and Bain, 1985; 
Li et al., 2012). Similarly, these cell lines were transiently transfected with the empty vector or the 
AR (indicated throughout by white bars) and either the classical ARE-luc, selective ARE-luc or  
ERE-luc promoter-reporter constructs (Fig. 3.2 C-H). These cells were treated with the classical 
potent, non-metabolisable synthetic androgen Mib, the natural ligand for the AR, DHT, or MPA, 
which is known to elicit AR agonist activity similar to that of DHT (Africander et al., 2014).  







































































































































































































































































































Figure 3.2: PRB and AR are transcriptionally active in promoter-reporter transactivation assays in both the  
MDA-MB-231 and PC3 cell lines. MDA-MB-231 breast cancer and PC3 prostate cancer cells were transiently 
transfected with 300 ng of the empty vector (pSG5) (grey bars; A-H) or pSG5-hPR-B (blue bars; A-B) and 3000 ng of 
the pTAT-PRE-E1b-luc reporter construct, or 300 ng of the pSG5-hAR (white bars; C-H) and 3000 ng of either the  
pTAT-PRE-E1b-luc (C-D), 4xSC-ARE1.2 (E-F) or the 2xERE-pS2-pGL3 reporter constructs (G-H). The next day, the 
cells were treated with 0.2% v/v vehicle control or 1 nM ligand for 24 hours. Luciferase activity was measured and 
normalized to total protein concentration. Fold induction is shown with the vehicle control set as 1 and all other responses 
set relative to this. The results indicate the average of at least two independent experiments for all ligands except Mib (C), 
with each condition performed in triplicate (±SEM). Statistical analysis was performed using column statistics and a one-
way ANOVA with a Newman-Keuls (comparing all pairs of columns) post-test. 




Figure 3.2 A-B shows significant activation of the PRE-luc via PRB in the presence of R5020, P4 and 
MPA in both the MDA-MB-231 and PC3 cell lines. Since no activation was observed in the absence 
of transfected receptor in either cell line, this confirms that the activation was due to the transfected 
PRB (Fig. 3.2 A-B). Significant activation of selective ARE by either Mib or DHT was also detected 
only in the presence of transfected AR in both cell lines (Fig. 3.2 E-F). In addition, DHT activated 
the classical ARE (Fig. 3.2 C-D) and ERE (Fig. 3.2 G-H) in both cell lines. The findings on the ERE 
are in line with the study by Peters et al. (2009) who showed that the AR could bind to the ERE. 
Surprisingly, although Mib also activated the ERE in both cell lines (Fig. 3.2 G-H), activation of the 
classical ARE by Mib was only observed in the PC3 cell line (Fig. 3.2 C-D). It should be noted that 
results for Mib on the classical ARE in the MDA-MB-231 cell line were from a single experiment  
(Fig. 3.2 C). Furthermore, MPA caused AR-mediated activation on the ERE in the MDA-MB-231 
(Fig. 3.2 G), but not PC3 (Fig. 3.2 H), cell line. Taken together, these results suggest that PRB is 
required for progestogen-induced activation of the PRE, while the AR is required for activation of all 
three response elements by Mib and DHT, except in the case of Mib on the classical ARE in the 
MDA-MB-231 cell line. 
3.3  Activation of PR isoforms by Mib and/or DHT, and the AR by R5020, are 
promoter- and/or cell line-dependent 
It is known that the AR and PR share 55% DNA sequence identity within their LBD (Gao et al., 
2005), and that MPA is a potent agonist for both receptors (Poulin et al., 1989; Africander et al., 
2014), while the potent PR agonist, P4, elicits very weak AR agonist activity on both the classical and 
selective AREs (Poulin et al., 1989; Africander et al., 2014). Thus, we next investigated whether the 
other AR and PR ligands (Mib, DHT and R5020) employed in this study could also elicit off-target 
effects via these receptors on the various response elements. Here, we included both PRB and PRA 
as the respective receptors were co-expressed with the AR in subsequent experiments. MDA-MB-
231 and PC3 cell lines were transiently transfected with either the empty vector, PRB, PRA or the 
AR, and either the PRE/classical ARE-luc, selective ARE-luc or ERE-luc. Cells transfected with PRB  
(Fig. 3.3) or PRA (Fig. 3.4) were treated with Mib or DHT, while those transfected with the AR were 




























































































































































































Figure 3.3: Mib modulates PRB activity in a cell line- and promoter-specific manner, while DHT is a PR agonist 
only via PRE in both MDA-MB-231 and PC3 cells. MDA-MB-231 breast cancer and PC3 prostate cancer cells were 
transiently transfected with 300 ng of pSG5-hPR-B (blue bars; A-F) and 3000 ng of the pTAT-PRE-E1b-luc (A-B),  
4xSC-ARE1.2 (C-D) or the 2xERE-pS2-pGL3 reporter constructs (E-F). The next day, the cells were treated with  
0.2% v/v vehicle control or 1 nM Mib or DHT for 24 hours. Luciferase activity was measured and normalized to total 
protein concentration. Fold induction is shown with the vehicle control set as 1 and all other responses set relative to this. 
The results indicate the average of at least two independent experiments for all ligands except Mib (A), with each 
condition performed in triplicate (±SEM). Statistical analysis was performed using a one-way ANOVA with a Newman-
Keuls (comparing all pairs of columns) post-test. 
 


















































































































































































Figure 3.4: Mib displays agonist activity via PRA only on the selective ARE in both cell lines, while DHT is only a 
PRA agonist via the ERE in the MDA-MB-231 cell line. MDA-MB-231 breast cancer and PC3 prostate cancer cells 
were transiently transfected with 300 ng of pSG5-hPR-A (pink bars; A-F) and 3000 ng of the pTAT-PRE-E1b-luc (A-B), 
4xSC-ARE1.2 (C-D) or the 2xERE-pS2-pGL3 reporter constructs (E-F). The next day, the cells were treated with  
0.2% v/v vehicle control or 1 nM Mib or DHT for 24 hours. Luciferase activity was measured and normalized to total 
protein concentration. Fold induction is shown with the vehicle control set as 1 and all other responses set relative to this. 
The results indicate the average of at least two independent experiments for all ligands except Mib (A), with each 
condition performed in triplicate (±SEM). Statistical analysis was performed using a one-way ANOVA with a Newman-
Keuls (comparing all pairs of columns) post-test. 
































































































































































































Figure 3.5: R5020 increased AR-mediated activation at the classical ARE and selective ARE in a cell line-specific 
manner, while ERE activity was similarly increased in both the MDA-MB-231 and PC3 cell lines. MDA-MB-231 
breast cancer and PC3 prostate cancer cells were transiently transfected with 300 ng of the empty vector (pSG5)  
(grey bars; A-F) or pSG5-hAR (white bars; A-F) and 3000 ng of the pTAT-PRE-E1b-luc (A-B), 4xSC-ARE1.2 (C-D) or 
the 2xERE-pS2-pGL3 reporter constructs (E-F). The next day, the cells were treated with 0.2% v/v vehicle control or  
1 nM R5020 for 24 hours. Luciferase activity was measured and normalized to total protein concentration. Fold induction 
is shown with the vehicle control set as 1 and all other responses set relative to this. The results indicate the average of at 
least two independent experiments, with each condition performed in triplicate (±SEM). Statistical analysis was 
performed using column statistics and a one-way ANOVA with a Newman-Keuls (comparing all pairs of columns) post-
test.  
 




The results in figure 3.3 indicate that DHT has significant agonist activity via PRB on the PRE, but 
not the selective ARE or ERE, in both the MDA-MB-231 and PC3 cell lines. Mib on the other hand, 
activated the PRE and ERE via PRB in only the PC3 cell line (Fig. 3.3 B, F), while significantly 
increasing the activity of the selective ARE in the MDA-MB-231 cell line (Fig. 3.3 C). Neither Mib 
nor DHT displayed any agonist activity via PRA on the PRE in the MDA-MB-231 or PC3 cell lines 
(Fig. 3.4 A-B), while Mib, but not DHT, acts as a PRA agonist on the selective ARE in these cell 
lines (Fig. 3.4 C-D). Interestingly, DHT showed agonist activity via PRA on the ERE in the  
MDA-MB-231 cell line (Fig. 3.4 E), but not in the PC3 cell line (Fig. 3.4 F), while Mib had no agonist 
activity in either cell line (Fig. 3.4 E-F). The results in figure 3.5 indicate that R5020 is an AR agonist 
on the classical ARE, selective ARE and ERE in the MDA-MB-231 cell line (Fig. 3.5 A, C, E), while 
it displayed significant AR agonist activity on only the ERE in the PC3 cell line (Fig. 3.5 F). No 
activation was observed on the response elements in the presence of Mib and DHT (Fig. 3.2 C-H), or 
R5020 (Fig. 3.5), in the MDA-MB-231 and PC3 cell lines transfected with an empty vector. 
Mib and R5020 were initially included in this study due to their reported selectivities for the AR and 
PR, respectively. As we showed that this is in fact not the case in our cell lines, Mib and R5020 were 
excluded from future experiments and further investigations were limited to the effects of the natural 
AR and PR ligands, DHT and P4, as well as the androgenic progestin MPA. 
3.4  Co-expression of unliganded PRB or PRA with the AR differentially modulated 
response element activity in a cell line- and/or promoter-specific manner 
Given that the AR can bind to an ERE in the promoter of the PR gene (Peters et al., 2009), and that 
blockade of AR activity abrogates PR expression in a preclinical breast cancer model (Wellberg et 
al., 2017), it is likely that the AR regulates PR expression. Indeed, it is known that the AR and PR 
are co-expressed in a subset of breast cancers (Ogawa et al., 2008; Niemeier et al., 2010; Park et al., 
2010). Considering that crosstalk between co-expressed steroid receptors plays a critical role in breast 
cancer, we next wanted to investigate the effects of AR and PR co-expression on the activity of the 
selected response elements in breast cancer cells. Since it is known that PRB and PRA can 
differentially regulate gene expression in breast cancer, we investigated the effects of both PR 
isoforms. As the PR is also expressed in prostate cancer tumours (Bonkhoff et al., 2001; Grindstad et 
al., 2015), we followed a similar investigation in prostate cancer cells.  
  




The MDA-MB-231 and PC3 cell lines were thus transiently transfected with 300 ng of the AR and 
3000 ng of either the classical ARE-luc, selective ARE-luc or ERE-luc, in the absence and presence 
of equimolar (1x) or excess (5x) concentrations of PRB or PRA (indicated throughout by pink bars) 
(Fig. 3.6 – 3.7). Changes in activity in the presence of both the AR and the unliganded PR isoforms 
were measured relative to the AR with 1 nM DHT set as 100%. The results show that co-expression 
of equimolar and excess unliganded PRB with the AR significantly increased activity on the classical 
ARE in the MDA-MB-231 cell line (Fig. 3.6 A), while unliganded PRA decreased classical ARE 
activity (Fig. 3.7 A). Similar results were observed in the PC3 cell line (Fig. 3.6 B, 3.7 B). In contrast, 
selective ARE activity was not modulated by the presence of either concentration of PRB in  
MDA-MB-231 cells (Fig. 3.6 C), while the activity was increased with an equimolar concentration 
of PRA (Fig. 3.7 C). In the PC3 cell line, excess PRB increased selective ARE activity (Fig. 3.6 D), 
while neither concentration of PRA had an effect (Fig. 3.7 D). Interestingly, ERE activity was 
increased in the presence of equimolar and excess PRB in both the MDA-MB-231 (Fig. 3.6 E) and 
PC3 (Fig. 3.6 F) cell lines, while for PRA similar results were obtained only at the highest 
concentration (Fig. 3.7 E-F). Taken together, the data suggests that co-expression of the AR and 
unliganded PRB or PRA can differentially modulate activity on the response element(s) when 
compared to AR alone in both the MDA-MB-231 and PC3 cell lines.  
In an attempt to explain the observed changes in response element activity when the AR and either 
PRB (Fig. 3.6) or PRA (Fig. 3.7) were co-expressed, we next investigated AR expression levels in 
the absence and presence of either PR isoform (Fig. 3.8). Western blot analysis showed that transient 
transfection of excess PRB or PRA resulted in appropriate increases (~5-fold) in PR protein 
expression in both the MDA-MB-231 and PC3 cell lines (Fig. 3.8 A-C). Moreover, the results in 
figure 3.8 D-F show that co-expression of equimolar AR and PRB or PRA did not affect AR 
expression in either cell line, while excess PRB and PRA decreased AR expression in both cell lines. 
3.5  Transcriptional activation in cells co-expressing the AR with liganded PRB is 
dependent on the specific PR ligand, response element and cell line used 
Since we have shown that co-expression of the AR with unliganded PRB modulated response element 
activity in a cell line- and promoter-specific manner, we next investigated how this activity would be 
influenced when the AR is activated by DHT, and PRB by its natural ligand, P4, or by MPA, the 
synthetic PR ligand known to also activate the AR. MDA-MB-231 and PC3 cells transiently 
transfected with the AR and either the classical ARE-luc, selective ARE-luc or ERE-luc in the 
absence and presence of equimolar (1x) or excess (5x) concentrations of PRB were thus treated with 
DHT in the absence and presence of P4 or MPA (Fig. 3.9-3.11).  




























































































































































































































Figure 3.6: Co-expression of AR and equimolar or excess unliganded PRB increased AR activity on a classical 
ARE and ERE in the MDA-MB-231 and PC3 cell lines. MDA-MB-231 and PC3 cells were transiently transfected with 
300 ng of the pSG5-hAR (white bars; A-F) together with 3000 ng of either the pTAT-PRE-E1b-luc (A-B), 4xSC-ARE1.2 
(C-D) or 2xERE-pS2-pGL3 (E-F) reporter constructs in the absence and presence of 300 ng (1x) (blue bars; A-F) or  
1500 ng (5x) pSG5-hPR-B (green bars; A-F). The next day, the cells were treated with 0.2% v/v vehicle control or 1 nM 
DHT for 24 hours. Luciferase activity was measured and normalized to total protein concentration. Fold induction at  
1 nM DHT via AR only was set as 100% and all other responses set relative to this. The results indicate the average of at 
least two independent experiments, each performed in triplicate (±SEM). Statistical analysis was performed using column 
statistics and a one-way ANOVA with a Newman-Keuls (comparing all pairs of columns) post-test.  




























































































































































































































Figure 3.7: Co-expression of unliganded PRA with AR modulated classical ARE and ERE activity in a 
concentration-specific manner in both the MDA-MB-231 and PC3 cell line, while selective ARE activity was only 
influenced in the MDA-MB-231 cell line. MDA-MB-231 and PC3 cells were transiently transfected with 300 ng of the 
pSG5-hAR (white bars; A-F) together with 3000 ng of either the pTAT-PRE-E1b-luc (A-B), 4xSC-ARE1.2 (C-D) or 
2xERE-pS2-pGL3 (E-F) reporter constructs in the absence and presence of 300 ng (1x) (pink bars; A-F) or 1500 ng (5x) 
pSG5-hPR-A (red bars; A-F). The next day, the cells were treated with 0.2% v/v vehicle control or 1 nM DHT for  
24 hours. Luciferase activity was measured and normalized to total protein concentration. Fold induction at 1 nM DHT 
via AR was set as 100% and all other responses set relative to this (A-F). The results indicate the average of at least two 
independent experiments, each performed in triplicate (±SEM). Statistical analysis was performed using column statistics 
and a one-way ANOVA with a Newman-Keuls (comparing all pairs of columns) post-test. 





Figure 3.8 legend on next page. 
 
 




Figure 3.8: Overexpressing excess PR isoforms, but not equimolar concentrations, decreased overexpressed AR 
protein levels in the MDA-MB-231 breast and PC3 prostate cancer cell lines. Whole cell extracts were prepared from 
the MDA-MB-231 breast and PC3 prostate cancer cell lines transfected with either 300 ng (1x) or 1500 ng (5x)  
pSG5-hPR-B or pSG5-hPR-A in the absence (A) and presence of 300 ng pSG5-hAR (D). Protein lysates were analysed 
by western blotting, using antibodies specific to PRB, PRA, AR and GAPDH (loading control), respectively (A, D). 
Western blots were quantified using myImageAnalysis software (B, C, E, F). Protein expression with 1xPRB  
(blue bars; B) or 1xPRA (pink bars; C) was set as 1 and the expression of 5xPRB (green bars; B) or 5xPRA (red bars; C), 
respectively, set relative to this. AR expression in the absence of either PR isoform was set as 100% (white bars; E-F) 
and the expression of the AR in the presence of either PR isoform set relative to this. The results shown are from a single 
experiment. (-) indicates untransfected MDA-MB-231 and PC3 cells, while (+) indicates PC3 cells transiently transfected 
with either the PRA or PRB for the western blot of MDA-MB-231 lysates and vice versa.  
In the MDA-MB-231 cell line, although both P4 and MPA appeared to augment the increased AR 
transactivation function by the unliganded PRB on the classical ARE, only the effects of MPA were 
statistically significant (Fig. 3.9 A, C). Similarly, P4 and MPA significantly increased the activity of 
unliganded PRB on AR transactivation function in PC3 cells, but only at the 5x concentration  
(Fig. 3.9 B, D). Interestingly, the addition of equimolar P4 and DHT to MDA-MB-231 cells 
transfected with only the AR resulted in a significant decrease of DHT activity via the AR, suggesting 
that P4 is an AR antagonist on this response element (Fig. 3.9 A). Although unliganded PRB did not 
affect AR activity on the selective ARE in the MDA-MB-231 cell line (Fig. 3.6 C), results in  
figure 3.10 A show that the activity was significantly increased when PRB was activated by P4, albeit 
only at the 5xPRB concentration. In contrast, activation by MPA increased AR activity on the 
selective ARE at both concentrations of PRB (Fig. 3.10 C). In the PC3 cell line, however, the increase 
of AR transactivation function by excess unliganded PRB was augmented by the addition of P4 and 
MPA (Fig. 3.10 B, D). Although unliganded PRB did not modulate AR activity on the selective ARE 
in cells co-expressing equimolar concentrations of the AR and PRB, the activity was significantly 
increased in the presence of MPA (Fig. 3.10 D). Interestingly, the increased AR activity on the ERE 
observed in the presence of equimolar concentrations of the AR and unliganded PRB in the  
MDA-MB-231 cell line, was abrogated when PRB was activated by P4 (Fig. 3.11 A), but not MPA 
(Fig. 3.11 C). In the PC3 cell line, the increased AR transactivation by only the excess unliganded 
PRB was amplified by P4 and MPA (Fig. 3.11 B, D). Similar activity was observed for MPA in the 
MDA-MB-231 cell lines (Fig. 3.11 C). 













































































































































































Figure 3.9: Co-expression of PRB with AR affects classical ARE induction in a ligand- and concentration-specific 
manner in the MDA-MB-231 and PC3 cell lines, respectively. The MDA-MB-231 and PC3 cells were transiently 
transfected with 300 ng of the pSG5-hAR (white bars; A-D) together with 3000 ng of the pTAT-PRE-E1b-luc reporter 
construct in the absence and presence of 300 ng (1x) (blue bars; A-D) or 1500 ng (5x) pSG5-hPR-B (green bars; A-D). 
The next day, the cells were treated with 0.2% v/v vehicle control or 1 nM ligand(s) for 24 hours. Luciferase activity was 
measured and normalized to total protein concentration. Fold induction at 1 nM DHT via AR only was set as 100% and 
all other responses set relative to this. The results indicate the average of at least two independent experiments, each 
performed in triplicate (±SEM). Statistical analysis was performed using column statistics and a one-way ANOVA with 
a Newman-Keuls (comparing all pairs of columns) post-test. 
 
 









































































































































































Figure 3.10: Co-expression of liganded PRB with AR increased selective ARE activation in a concentration-
dependent manner in the MDA-MB-231 and PC3 cell lines. The MDA-MB-231 and PC3 cells were transiently 
transfected with 300 ng of the pSG5-hAR (white bars; A-D) together with 3000 ng of the 4xSC-ARE1.2 reporter construct 
in the absence and presence of 300 ng (1x) (blue bars; A-D) or 1500 ng (5x) pSG5-hPR-B (green bars; A-D). The next 
day, the cells were treated with 0.2% v/v vehicle control or 1 nM ligand(s) for 24 hours. Luciferase activity was measured 
and normalized to total protein concentration. Fold induction at 1 nM DHT via AR only was set as 100% and all other 
responses set relative to this. The results indicate the average of at least two independent experiments, each performed in 
triplicate (±SEM). Statistical analysis was performed using column statistics and a one-way ANOVA with a Newman-
Keuls (comparing all pairs of columns) post-test. 
 
 













































































































































































Figure 3.11: Co-expression of liganded PRB with AR increased ERE activation in a ligand- and concentration-
specific manner in the MDA-MB-231 and PC3 cell lines, respectively. The MDA-MB-231 and PC3 cells were 
transiently transfected with 300 ng of the pSG5-hAR (white bars; A-D) together with 3000 ng of the 2xERE-pS2-pGL3 
reporter construct in the absence and presence of 300 ng (1x) (blue bars; A-D) or 1500 ng (5x) pSG5-hPR-B  
(green bars; A-D). The next day, the cells were treated with 0.2% v/v vehicle control or 1 nM ligand(s) for 24 hours. 
Luciferase activity was measured and normalized to total protein concentration. Fold induction at 1 nM DHT via AR only 
was set as 100% and all other responses set relative to this. The results indicate the average of at least two independent 
experiments, each performed in triplicate (±SEM). Statistical analysis was performed using column statistics and a one-
way ANOVA with a Newman-Keuls (comparing all pairs of columns) post-test. 
 
 




When comparing AR activity on all response elements in the MDA-MB-231 and PC3 cell lines  
co-expressing the AR and excess liganded PRB, to cells expressing only the AR, it is evident that the 
activity is increased (Fig. 3.9-3.11). For cells co-expressing equimolar AR and PRB, the activity of 
the AR on the ERE and selective ARE were increased by MPA, but not P4, in the MDA-MB-231 
(Fig. 3.11 A, C) and PC3 cells (Fig. 3.10 B, D), respectively. On the other hand, AR activity on the 
classical ARE was increased in response to both P4 and MPA at only the excess concentration of PRB 
in the PC3 cell line (Fig. 3.9 B, D), while both PRB concentrations increased AR activity in the MDA-
MB-231 cell line (Fig. 3.9 A, C). Taken together, transcriptional activity in the presence of both AR 
and PRB and their ligands is promoter-, ligand- and cell line-specific. 
3.6  Liganded PRA did not affect AR-mediated activity on the classical ARE, but 
modulated selective ARE and ERE activity in a cell line-, ligand- or concentration-
specific manner  
Next, we investigated whether liganded PRA would elicit similar effects as PRB when co-expressed 
with the AR. MDA-MB-231 and PC3 cell lines were transfected with the AR and either the classical 
ARE-luc, selective ARE-luc or ERE-luc in the absence and presence of equimolar (1x) or excess (5x) 
concentrations of PRA, and the cells treated as in Section 3.5.  
The results show that inhibition of AR transactivation function by unliganded PRA on the classical 
ARE was not modulated by the presence of the PR ligands in both the MDA-MB-231 and PC3 cell 
lines (Fig. 3.12). At equimolar concentrations of AR and PRA in the MDA-MB-231 cells, the effect 
of unliganded PRA on AR activity on the selective ARE was increased by P4, but not MPA (Fig. 3.13 
A, C). In contrast, MPA, but not P4, augmented the increase in AR transactivation function by excess 
PRA on the ERE (Fig. 3.14 A, C). In the PC3 cell line expressing excess PRA relative to AR, both 
P4 and MPA increased the transcriptional activity of the AR on the selective ARE  
(Fig. 3.13 B, D), while abrogating the effect of unliganded PRA on the ERE (Fig. 3.14 B, D).  
When comparing AR activity in the MDA-MB-231 and PC3 cell lines co-expressing the AR and 
equimolar PRA, to cells expressing only the AR, transactivation is increased on the selective ARE in 
only the MDA-MB-231 cell line when P4 and MPA are added (Fig. 3.13 A, C). Similarly, in the 
presence of the AR and excess PRA, both P4 and MPA increased AR activity on the ERE in the  
MDA-MB-231 cell line (Fig. 3.14 A, C), and on the selective ARE in the PC3 cell line  
(Fig. 3.13 B, D). In summary, although the liganded PRA does not influence the effects of DHT via 
the AR on the classical ARE, effects on the selective ARE and ERE are modulated in a cell line-, 
promoter or ligand-dependent manner. 


































































































































































Figure 3.12: Liganded PRA did not affect the inhibition of AR activity by unliganded PRA. The MDA-MB-231 and 
PC3 cells were transiently transfected with 300 ng of the pSG5-hAR (white bars; A-D) together with 3000 ng of the 
pTAT-PRE-E1b-luc reporter construct in the absence and presence of 300 ng (1x) (pink bars; A-D) or 1500 ng (5x)  
pSG5-hPR-A (red bars; A-D). The next day, the cells were treated with 0.2% v/v vehicle control or 1 nM ligand(s) for  
24 hours. Luciferase activity was measured and normalized to total protein concentration. Fold induction at 1 nM DHT 
via AR only was set as 100% and all other responses set relative to this. The results indicate the average of at least three 
independent experiments, each performed in triplicate (±SEM). Statistical analysis was performed using column statistics 
and a one-way ANOVA with a Newman-Keuls (comparing all pairs of columns) post-test. 
 
 




































































































































































Figure 3.13: The influence of the liganded PRA on AR activity via the selective ARE is dependent on PR 
concentration and the cell line used. The MDA-MB-231 and PC3 cells were transiently transfected with 300 ng of the 
pSG5-hAR (white bars; A-D) together with 3000 ng of the 4xSC-ARE1.2 reporter construct in the absence and presence 
of 300 ng (1x) (pink bars; A-D) or 1500 ng (5x) pSG5-hPR-A (red bars; A-D). The next day, the cells were treated with 
0.2% v/v vehicle control or 1 nM ligand(s) for 24 hours. Luciferase activity was measured and normalized to total protein 
concentration. Fold induction at 1 nM DHT via AR only was set as 100% and all other responses set relative to this. The 
results indicate the average of at least three independent experiments, each performed in triplicate (±SEM). Statistical 










































































































































































Figure 3.14: Liganded excess PRA modulated AR activity on the ERE in a ligand- and cell line-specific manner. 
MDA-MB-231 and PC3 cells were transiently transfected with 300 ng of the pSG5-hAR (white bars; A-D) together with 
3000 ng of the 2xERE-pS2-pGL3 reporter construct in the absence and presence of 300 ng (1x) (pink bars; A-D) or  
1500 ng (5x) pSG5-hPR-A (red bars; A-D). The next day, the cells were treated with 0.2% v/v vehicle control or 1 nM 
ligand(s) for 24 hours. Luciferase activity was measured and normalized to total protein concentration. Fold induction at 
1 nM DHT via AR only was set as 100% and all other responses set relative to this. The results indicate the average of at 
least three independent experiments, each performed in triplicate (±SEM). Statistical analysis was performed using 
column statistics and a one-way ANOVA with a Newman-Keuls (comparing all pairs of columns) post-test. 
 




3.7  PRB can transactivate via the selective ARE and ERE, while PRA activates the 
classical and selective AREs and the ERE in a ligand-specific manner 
We have shown that liganded equimolar (1x) and excess (5x) PR isoforms differentially modulate 
AR activity on all the response elements used in this study (Fig. 3.9-14), and that both the AR and 
PR isoforms can activate these response elements in the presence of androgens (Fig. 3.2-3.4). Thus, 
we next wanted to determine the extent to which PR ligands would activate these response elements 
via the PR isoforms. MDA-MB-231 and PC3 cell lines transiently transfected with either 300 ng (1x) 
or 1500 ng (5x) PRB (Fig. 3.15) or PRA (Fig. 3.16) and either the selective ARE-luc, ERE-luc or 
PRE-luc, were thus treated with 1 nM of R5020, P4 or MPA. Cells were also transfected with the 
empty vector as a control to determine whether transactivation was indeed via the overexpressed PR 
isoforms.   
In both cell lines, only R5020 displayed significant agonist activity via 1xPRB on the selective ARE, 
while all ligands increased activation of excess PRB on this response element (Fig. 3.15 A-B), 
suggesting that the selective ARE is not AR-specific as previously reported (Verrijdt et al., 1999). 
PRB-mediated activity on the ERE was increased by all PR ligands in both cell lines in the presence 
of excess PRB (Fig. 3.15 C-D). At the 1xPRB, however, only P4 and MPA significantly activated 
PRB via ERE in the MDA-MB-231 cell line (Fig. 3.15 C), while only R5020 induced a significant 
increase in the PC3 cell line (Fig. 3.15 D). As expected, the PR ligands activated PRB via PRE in a 
concentration-dependent manner in both the MDA-MB-231 and PC3 cell lines (Fig. 3.15 E-F). 
None of the PR ligands activated 1xPRA in the MDA-MB-231 and PC3 cell lines (Fig. 3.16). 
However, in both cell lines transfected with excess PRA, R5020 and MPA, but not P4, induced 
significant increases in PRA activity via the selective ARE (Fig. 3.16 A-B). Although PRA was not 
activated by any ligand on the ERE in the PC3 cell line (Fig. 3.16 D), only MPA caused activation in 
the MDA-MB-231 cell line transfected with excess PRA (Fig. 3.16 C). Surprisingly, the PR ligands 
activated excess, but not equimolar, PRA on the PRE in both the MDA-MB-231 and PC3 cell lines 
(Fig. 3.16 E-F).  
In summary, the results indicate that the progestogens differentially induced PR isoform 
transactivation via the ERE and selective ARE in the MDA-MB-231 and PC3 cell lines in a PR 
concentration-dependent manner. 



















































































































































































































































Figure 3.15: PR ligands differentially induced PRB-mediated transactivation via the selective ARE and ERE in 
the MDA-MB-231 and PC3 cell lines. MDA-MB-231 and PC3 cells were transiently transfected with 300 ng of the 
empty vector (pSG5) (grey bars; A-F), or 300 ng (1x) (blue bars; A-F) or 1500 ng (5x) pSG5-hPR-B (green bars; A-F), 
together with 3000 ng of either the 4xSC-ARE1.2 (A-B), 2xERE-pS2-pGL3 (C-D) or pTAT-PRE-E1b-luc (E-F) reporter 
constructs. The next day, the cells were treated with 0.2% v/v vehicle control or 1 nM ligand for 24 hours. Luciferase 
activity was measured and normalized to total protein concentration. The fold induction is shown with the vehicle control 
of each transfection condition set as 1 and all other responses set relative to this. The results indicate the average of at 
least four independent experiments, each performed in triplicate (±SEM). Statistical analysis was performed using column 
statistics and a one-way ANOVA with a Newman-Keuls (compares all pairs of columns) post -test. 
















































































































































































































Figure 3.16: Progestogens differentially induce transactivation on the selective ARE and ERE only in the presence 
of excess PRA. MDA-MB-231 and PC3 cells were transiently transfected with 300 ng of the empty vector (pSG5)  
(grey bars; A-F), or 300 ng (1x) (pink bars; A-F) or 1500 ng (5x) pSG5-hPR-A (red bars; A-F), together with 3000 ng of 
either the 4xSC-ARE1.2 (A-B), 2xERE-pS2-pGL3 (C-D) or pTAT-PRE-E1b-luc (E-F) reporter constructs. The next day, 
the cells were treated with 0.2% v/v vehicle control or 1 nM ligand for 24 hours. Luciferase activity was measured and 
normalized to total protein concentration. The fold induction is shown with the vehicle control of each transfection 
condition set as 1 and all other responses set relative to this. The results indicate the average of at least four independent 
experiments, each performed in triplicate (±SEM). Statistical analysis was performed using a column statistics and a  
one-way ANOVA with a Newman-Keuls (compares all pairs of columns) post -test. 
 




3.8  No proliferation was observed in the MDA-MB-231 and PC3 cell lines transiently 
transfected with the AR 
Next, we wanted to investigate whether AR-mediated effects on breast and prostate cancer cell 
proliferation were influenced by either PRA or PRB. First, we used both the MTT (Fig. 3.17 A-B) 
and Alamar blue (Fig. 3.17 C-D) cell proliferation assays to determine the effects of DHT via the AR 
on proliferation of the MDA-MB-231 and PC3 cell lines. These cell lines were thus transiently 
transfected with either the empty vector or the expression vector for the AR and treated with  
0.2% vehicle or 1 nM DHT. As expected, results indicated no proliferation of the MDA-MB-231 and 
PC3 cell lines in the absence of transfected steroid receptor (empty vector). However, proliferation 
was also not observed in these cell lines when transiently transfected with the AR. Thus, we were 
unable to investigate the effects of AR-mediated proliferation of the MDA-MB-231 and PC3 cell 



















































































































Figure 3.17: No proliferation was observed in the MDA-MB-231 and PC3 cell lines transiently transfected with 
the AR. MDA-MB-231 and PC3 cell lines were transiently transfected with 300 ng of either the empty vector (pSG5) 
(grey bars; A-D) or the expression vector for the human AR (pSG5-hAR) (white bars; A-D). After 24 hours, the cells 
were treated with 0.2% v/v vehicle control or 1 nM DHT for 72 hours, and then re-treated with new compounds and 




incubated for a further 48 or 168 hours for the MTT and Alamar blue assays, respectively. The fold proliferation was 
determined by setting the proliferation in the presence of the vehicle as 1 and all other responses relative to that. The 
results indicate the average of one (C-D) or four (A-B) independent experiment(s), each performed in triplicate (±SEM). 
Statistical analysis was performed using column statistics and a one-way ANOVA with a Newman-Keuls (comparing all 
pairs of columns) post-test.


























Steroid receptors play an important role in both breast and prostate cancer development. The role of 
the ER is well-established in breast cancer, while that of the AR is well-described in prostate cancer 
(Sommer and Fuqua, 2001; Shafi et al., 2013). However, the AR is also expressed in about 70-90% 
of breast cancer tumours and is suggested to play an anti-oncogenic role in ER-positive breast cancer 
(Peters et al., 2009; Park et al., 2010; Rizza et al., 2014). For example, the AR has been shown to 
decrease ERα-mediated proliferation (Peters et al., 2009) and increase the expression of anti-
proliferative ERβ (Rizza et al., 2014). The PR, although previously thought of as merely a marker of 
ER functionality, has also recently been reported to contribute to breast cancer development (Ravdin 
et al., 1992; Hopp, 2004; Allred et al., 2012; Onoda et al., 2015). Interestingly, while a number of 
studies have previously shown that the AR and PR are co-expressed in breast cancer (Isola, 1993; 
Ogawa et al., 2008; Niemeier et al., 2010; Park et al., 2010), a very recent study by Wellberg et al. 
(2017) showed that a functional AR is required for PR expression in a post-menopausal model of 
obesity-induced breast cancer. These results suggest that the AR, like the ER, may be upregulating 
the expression of the PR gene by a mechanism involving binding of the AR to the ERE in the promoter 
of the gene. Indeed, Peters et al. (2009) have previously shown that the AR can bind to the ERE in 
the promoter of the PR gene. Interestingly, it has recently also been shown that the natural androgen 
DHT regulates the expression of both PR isoforms, PRA and PRB, via the AR in human endometrial 
explants (Babayev et al., 2017). Thus, it is likely that the AR will also drive PR isoform expression 
in prostate cancer, suggesting that the AR and PR may also be co-expressed in prostate cancer. Indeed, 
it is known that the PR is expressed in prostate cancer tumours and that its expression is increased 
with tumour progression (Bonkhoff et al., 2001; Grindstad et al., 2015). To the best of our knowledge, 
there are currently no studies investigating the possible crosstalk between the AR and PR in breast or 
prostate cancer. As the AR and PR may contribute to the development of breast and prostate cancer 
by upregulating the expression of genes known to be involved in the development and progression of 
these cancers, we investigated the transactivation of gene expression in this study. We focussed on 
the transactivation function of the AR and PR isoforms on different steroid response elements in the 
MDA-MB-231 breast cancer and PC3 prostate cancer cell lines. Specifically, we used the classical 
ARE/PRE that both the AR and PR isoforms are known to activate (Beato et al., 1996), the selective 
ARE which is reported to be AR-specific (Verrijdt et al., 1999), as well as the binding motif for the 
ER, the ERE, since the AR has previously been shown to bind to this response element (Peters et al., 
2009). Most importantly, we investigated whether AR transactivation function on these steroid 
response elements was modulated by the presence of PRB or PRA. 




 Validating the model system  
First, we confirmed previous reports in the literature indicating that the MDA-MB-231 breast cancer 
cell line and PC3 prostate cancer cell line do not endogenously express the PR isoforms or the AR 
(Fig. 3.1) (Lin et al., 2001; Lai et al., 2009; Nowakowska et al., 2016). Reports of GR expression in 
the MDA-MB-231 cell line (Abduljabbar et al., 2015; Fietz et al., 2017) and ERα expression in the 
PC3 cell line (Kim et al., 2002) were also confirmed. Although it has previously been shown that 
ERβ is present in the PC3 cell line (Kim et al., 2002), we did not detect ERβ expression in these cells, 
likely due to the lack of an optimal ERβ antibody (Fig. 3.1). Nonetheless, the results suggested that 
the MDA-MB-231 and PC3 cell lines were appropriate model cell lines for comparing the activities 
of the AR and PR isoforms. 
Next, we validated the promoter-reporter assays in the MDA-MB-231 and PC3 cell lines by showing 
that PRB was transcriptionally active via the PRE in the presence of the PR ligands, R5020, P4 and 
MPA (Fig. 3.2 A-B) (Vegeto et al., 1993; Hagan et al., 2011; Izzo et al., 2014). Since the PRE also 
serves as a classical ARE (Africander et al., 2014), we showed that the AR was able to activate this 
response element, as well as the selective ARE, in the presence of the androgens, Mib and DHT  
(Fig. 3.2 C-F). Unexpectedly, no activation was observed for the progestin MPA (Fig. 3.2 C-F), which 
has previously been shown to induce AR activation on both the classical and selective AREs in the  
COS-1 monkey kidney cell line (Africander et al., 2014). The difference in response between this 
study and that of Africander and co-workers may be due to differences in the amount of transfected 
AR and the use of different cell lines. Finally, in agreement with the study by Peters et al. (2009) who 
showed that DHT-bound AR could bind to the ERE, we showed that DHT activated the 
transactivation function of the AR via an ERE in both the MDA-MB-231 and PC3 cell lines  
(Fig. 3.2 G-H). Interestingly, Mib, but not MPA, also induced AR-mediated ERE activation in both 
cell lines (Fig. 3.2 G-H), while MPA only caused this response in the MDA-MB-231 cell line  
(Fig 3.2 G). These results suggest that the effects of MPA via the AR on an ERE are cell-specific and 
may be attributed to the fact that different cell lines may express different co-activators that are needed 
for transcription (Beato et al., 1996). In addition, since it is known that MPA can be metabolised 
(Utaaker et al., 1988; Kobayashi et al., 2000; Mimura et al., 2003), cell-specific responses to MPA 
may also be due to differences in the metabolism of MPA between these cell lines.  
Prior to co-expressing the AR with PRA or PRB, we determined whether the AR and PR ligands used 
in this study were specific to their respective receptors. The initial rationale was to use Mib to activate 
the AR and determine whether PRA or PRB could influence AR-mediated transactivation, as this 
ligand is frequently used in the literature as an AR-specific agonist (Miki et al., 1988). However, we 




found that Mib exhibited significant progestogenic activity via PRB in a cell line- and promoter-
specific manner (Fig. 3.3), while only displaying activity via PRA on the selective ARE (Fig. 3.4). 
Upon closer inspection of the literature, we found a study from many years ago showing that Mib 
could bind to the PR in the human prostate with comparable affinity to the potent synthetic PR agonist, 
R5020 (Murthy et al., 1986). However, binding affinity is a poor indicator of transcriptional activity 
(Bain et al., 2014), and the study by Murthy and co-workers did not indicate whether Mib has PR 
agonist or antagonist activity. Although this study also did not specify which PR isoform Mib bound 
to, another study has shown that Mib decreased MCF-7 breast cancer cell proliferation via both PRB 
and PRA (Cops et al., 2008). Considering that Mib is widely used as an AR-specific agonist in the 
steroid receptor field, our results highlight the previously underappreciated fact that Mib may also be 
a PR agonist. Thus, caution should be exercised when interpreting the effects of Mib on 
transactivation via specific response elements in a system that expresses both the AR and PR.  
Interestingly, the natural ligand for the AR, DHT, showed significant agonist activity via PRB on the 
classical ARE in both cell lines (Fig. 3.3 A-B), while only activating PRA on the ERE in the  
MDA-MB-231 cell line (Fig. 3.4 E). These results are consistent with another study in which DHT 
was found to have agonist activity via PRB, but not PRA, on a PRE/classical ARE in the human T47D 
breast cancer cell line (Ghatge et al., 2005). Interestingly, increased expression of the PSA gene, a 
prostate cancer marker which contains a classical ARE in its promoter (Lai et al., 2009), has been 
associated with increased breast cancer tumour size and histological grade (Black et al., 2000). Thus, 
the fact that DHT was able to induce PRB-mediated classical ARE activation in the PC3 cell line may 
provide a putative mechanism through which increased PR expression may lead to prostate cancer 
progression (Bonkhoff et al., 2001; Grindstad et al., 2015).  
Surprisingly, we also found that R5020 induced AR-mediated activation via all the response elements 
in the MDA-MB-231 cell line (Fig. 3.5 A, C, E), but only on the ERE in the PC3 cell line  
(Fig. 3.5 F). These results indicating that R5020 is not PR-specific is in agreement with a study 
showing that it binds the GR (Lippman et al., 1976), and suggests that caution should also be exercised 
when interpreting the effects of R5020 on the transactivation of ERE-containing target genes in a 
system that expresses both the AR and PR. Due to the lack of receptor specificity of Mib and R5020, 
we thus excluded both of these ligands from the co-expression studies. Although we showed that 
DHT was also not AR-specific, we continued using DHT as it is the natural ligand for the AR.   
 




 Unliganded PRB and PRA differentially modulated AR transactivation function 
via the different response elements 
Having validated the proposed experimental model systems, we next investigated the effects of PRB 
and PRA on AR-mediated transactivation in the absence of PR ligands. The results showed that  
co-expression of equimolar or excess PRB with AR in the absence of PR ligands increased AR 
activity on the classical ARE and ERE in a PRB concentration-dependent manner in the  
MDA-MB-231 and PC3 cell lines (Fig. 3.6 A-B, E-F). In contrast, AR activity was increased only on 
the selective ARE in the PC3 cell line transfected with excess PRB (Fig. 3.6 C-D).  
Understanding the role of the AR and PR isoforms when they are co-expressed is not straightforward. 
As we have shown that DHT is an agonist of both the AR and PRB on the classical ARE in the  
MDA-MB-231 and PC3 cell lines (Figs. 3.2 C-D; 3.3 A-B), either one or both receptors could be 
contributing to the observed increase in response. In an attempt to understand this conundrum, the 
combined data in figures 3.3 A-B and 3.6 A-B were re-plotted to show how the presence of the AR 
influences the activity of DHT via PRB (Fig. 4.1 A-B). When the data is presented in this manner, 
the results show that the activity of PRB on the classical ARE is significantly increased in the presence 
of the AR, and that neither the AR (Fig. 3.2 C-D) nor PRB (Fig. 4.1 A-B) alone could induce the 
increased relative fold induction observed when these receptors are co-expressed  
(Fig. 3.6 A-B). Collectively, these results suggest that both the AR and PR are required for the 
increased response observed on the classical ARE (Fig. 3.6 A-B). Since it is known that the AR and 
GR can form functional heterodimers (Chen et al., 1997), and considering the structural similarities 
between the AR and PR isoforms, it is likely that this increase in activity may be due to a direct 
interaction between the AR and PRB.  
When investigating the effects of PRA on AR activity, the results showed that PRA decreased  
AR-mediated activity on the classical ARE at both concentrations of PRA in the MDA-MB-231 cell 
line, but only at the excess concentration in the PC3 cell line (Fig. 3.7 A-B). Interestingly, a study by 
Vegeto et al. (1993) has previously shown that PRA decreases AR-mediated transactivation on the 
classical ARE/PRE-containing mouse mammary tumour virus (MMTV)-luc promoter transfected 
into CV-1 monkey kidney cells. In addition, the results from the western blot analysis (Fig. 3.8 D, F) 
indicated that inhibition of AR activity by excess PRA may be due to PRA decreasing AR protein 
levels. However, as both the AR and excess PRA can activate the classical ARE  
(Fig. 3.2 C-D; 3.16 E-F), the decrease in AR activity in the presence of the excess concentration of 
PRA in both cell lines (Fig. 3.7 A-B) may also be due to these receptors competing for binding to the 
response element. In contrast to the results on the classical ARE, an increase in AR transactivation 




on the selective ARE was observed with only equimolar unliganded PRA in the MDA-MB-231 cell 
line (Fig. 3.7 C), while neither PR concentration had an effect on AR activity on this response element 
in the PC3 cell line (Fig. 3.7 D). Although the precise mechanism for the increase at the equimolar, 
but not excess, PRA concentration (Fig. 3.7 C)  is not known, results from the western blot analysis 
(Fig. 3.8 D, F) showed that the increase in AR activity is not due to increased AR expression, as AR 
protein expression was not modulated by equimolar PRA (Fig. 3.8 D, F). The fact that excess PRA 
had no effect on AR transactivation function (Fig. 3.7 C), while decreasing AR expression  
(Fig. 3.8 D, F) suggests that the relative expression levels of PRA to AR determine AR activity on 
the selective ARE when these receptors are co-expressed in the MDA-MB-231 cell line.  
The fact that DHT displayed agonist activity via both the AR and PRA on the ERE in the  
MDA-MB-231 cell line (Figs. 3.2 G; 3.4 E), suggests that the increase in ERE activation upon  
co-expression of excess PRA with AR may also be mediated by either or both receptors (Fig. 3.7 E). 
To gain an understanding of the role of these receptors, the data in figure 3.7 E was re-plotted to 
observe how the effects of PRA on the ERE were modulated in the presence of the AR (Fig. 4.1 C). 
Yet again, the replotted data indicated that both receptors were involved in the increased response 
observed on the ERE (Fig. 3.7 E). In contrast, since DHT did not induce PRA activity via the ERE in 
PC3 cells (Fig. 3.4 F), the increased response by DHT on this response element, when the AR and 
PRA are co-expressed, is due to the PR augmenting the transactivation function of the AR  
(Fig. 3.2 H; Fig. 3.7 F).  
Taken together, the results indicate that both the AR and unliganded PRB or PRA are required for 
increased transactivation observed on the different response elements in both cell lines, with the 
exception of PRA on the classical ARE which decreased AR activity. The former results suggest that 
either PR isoform may augment AR transactivation on target genes containing the selective ARE or 
ERE, thereby increasing AR-mediated breast and prostate cancer tumorigenesis. However, PRA may 
also play a protective role when expressed with the AR by limiting AR-mediated effects on oncogenes 
containing a classical ARE/PRE sequence. Moreover, the fact that both P4 and DHT can increase PR 
transactivation function via the selective ARE and ERE suggests that the PR isoforms may regulate 
genes containing these response elements in their promoter regions, such as the PSA gene, a prostate 
cancer marker which, in addition to the classical ARE, also contains a selective ARE, or the  
ERE-containing bcl-2 gene which regulates apoptosis in breast cancer. This may explain a putative 
mechanism by which PR isoforms mediate oncogenic effects in breast and prostate cancer.  

































































































Figure 4.1: The AR increased equimolar and excess PRB transactivation function on the classical ARE in the 
MDA-MB-231 and PC3 cell lines, while increasing the activity of excess PRA on the ERE in the MDA-MB-231 cell 
line. MDA-MB-231 and PC3 cells were transiently transfected with 300 ng (1x) or 1500 ng (5x) pSG5-hPR-B and  
3000 ng of the pTAT-PRE-E1b-luc reporter construct in the absence and presence of 300 ng pSG5-hAR (A-B), or  
1500 ng (5x) pSG5-hPR-A and 3000 ng of the 2xERE-pS2-pGL3 reporter construct in the absence and presence of  
300 ng pSG5-hAR (C). The next day, the cells were treated with 0.2% v/v vehicle control or 1 nM DHT for 24 hours. 
Luciferase activity was measured and normalized to total protein concentration. The results are represented as fold 
induction relative to the vehicle control of each transfection condition. The results indicate the average of at least three 
independent experiments, each performed in triplicate (±SEM). Statistical analysis was performed using a column 
statistics and a one-way ANOVA with a Newman-Keuls (comparing all pairs of columns) post-test. 
 




 Liganded PRB and PRA differentially modulate AR activity 
Our investigations in the presence of the PR ligands, P4 and MPA, showed that the activated PRB 
increased AR activity on the selected response elements in a ligand-, cell line- and promoter-specific 
manner (Fig. 3.9-3.11). Although the presence of PR ligands did not modulate the decrease in AR 
transactivation function on the classical ARE by unliganded PRA (Fig. 3.12), the effects of liganded 
PRA on the selective ARE and ERE were dependent on the specific PR ligand, the concentration of 
PRA and the cell line (Fig. 3.13-3.14).  
The effects of steroid receptors are complex and dependent on various factors, including receptor 
density, the type of ligand, the context of the promoter landscape and the cellular milieu (Hager et 
al., 2009). It is known that different ligands induce different steroid receptor conformations, and that 
alterations of the LBD ultimately affect the structure of the DBD (Hager et al., 2009; Bain et al., 
2014). Indeed, P4 and MPA differ in their structures, and these ligands differentially modulate the 
conformation of the PR (Duax et al., 1978; Allan et al., 1992). In addition, it is known that the 
interaction of both P4 and MPA with the PR alters the conformation of the LBD, which influences 
the structure of the DBD and therefore determines the sequence to which the PR can bind (Duax et 
al., 1978; Raynaud et al., 1980; Spilman et al., 1986). As it is known that receptor density determines 
transcriptional activity and the biological character of a steroid hormone (Zhao et al 2003; Robertson 
et al., 2013), the concentration-dependent effects of the PR isoforms observed in this study could be 
explained by the fact that more PR protein was present to activate the various response elements  
(Fig. 3.8 A-C). The cell-specific differences observed in this study may be attributed to the fact that 
MDA-MB-231 breast cancer and PC3 prostate cancer cell lines each contain a unique milieu of 
transcriptional regulators (Litvinov et al., 2006; Conzen, 2008; Bhagwat and Vakoc, 2015). In 
addition, it is known that breast and prostate cancer cell lines differentially metabolise steroids (Raju 
et al., 1978; Koh et al., 2001), and that P4, MPA and DHT can be metabolised (Utaaker et al., 1988; 
Kobayashi et al., 2000; Ji et al., 2003; Wiebe, 2006), thus we cannot exclude the possibility that the 
ligands are metabolised in one cell line and not the other.  
The general trend observed that liganded PR isoforms increased AR activity in both the  
MDA-MB-231 and PC3 cell lines suggests that the transcriptional activation observed in the presence 
of either the AR or PR isoforms is magnified when these receptors are co-expressed. The exception 
to this was liganded PRA abrogating the increase on AR activity by unliganded PRA on the ERE in 
the PC3 cell line (Fig. 3.14 B, D) and liganded equimolar concentrations of PRB abrogating the 
increase on AR activity by unliganded PRB on the ERE in the MDA-MB-231 cell line (Fig. 3.11 A). 
Nevertheless, the results indicating increased activity may explain a mechanism through which 




increased expression of either PRB or PRA mediates prostate cancer progression (Grindstad et al., 
2015). For example, PRB may enhance AR-mediated effects at various oncogenes  
(Fig. 3.6; 3.9-3.11), or PRB itself could be activated by either P4 or DHT and activate genes encoding 
a classical ARE/PRE (Fig. 3.2 A-B; 3.3 A-B) in their promoters, such as the GATA3 gene known to 
mediate cell migration, or the PSA prostate cancer marker (Lai et al., 2009; Yin et al., 2012). The fact 
that excess liganded PRA abrogated the increased AR activity by unliganded PRA on the ERE in the 
PC3 cell line (Fig. 3.14 B, D) suggests that unliganded PRA may increase the transcriptional activity 
of the AR and thus promote prostate cancer, while the liganded PRA would not. In terms of breast 
cancer, tamoxifen is used to treat breast cancer patients and functions by inhibiting ER-mediated 
effects on EREs. However,  resistance occurs in some patients (Chang, 2012) and both the AR and 
PRA have been implicated in this resistance mechanism (Hopp, 2004; De Amicis et al., 2010; 
Rechoum et al., 2014; Ciupek et al., 2015). We have shown that both the AR and PRA can activate 
the ERE in the MDA-MB-231 cell line (Fig. 3.2 G; 3.16 C), suggesting that these receptors can mimic 
the role of the ER in breast cancer. Moreover, AR transactivation on the ERE is augmented by PRA 
in the MDA-MB-231 cell line (Fig. 3.14 A, C) co-expressing the AR and PRA.  
Taken together, these results show that crosstalk occurs between the AR and PR isoforms in both 
prostate and breast cancer, and may provide a mechanism through which these receptors mediate 
treatment failure in both cancers. 
 PRB and PRA differentially transactivate via the selective ARE and ERE 
While it is known that PRB and PRA can activate similar gene sets, there are some genes that are 
only regulated by PRA, and others that are predominantly regulated by PRB (Graham and Clarke, 
2002; Kariagina et al., 2008). Thus, it is not surprising that we showed that R5020, P4 and MPA, 
differentially induced PRB (Fig. 3.15) and PRA (Fig. 3.16) transactivation via the selective ARE and 
ERE in the MDA-MB-231 and PC3 cell lines. To the best of our knowledge, this is the first study to 
show that PRB and PRA can transactivate via these response elements in both breast and prostate 
cancer cells. Importantly, the fact that MPA induced both PRB and PRA transactivation on the ERE 
in the MDA-MB-231 breast cancer cell line (Fig. 3.15 C; 3.16 C) may provide a mechanism for the 
well-established link between MPA and increased breast cancer risk in women using MPA in 
hormone therapy (Collaborative Group on Hormonal Factors in Breast Cancer, 1996; Rossouw et al., 
2002; Beral and Million Women Study Collaborators, 2003; Chlebowski et al., 2003, 2009, 2013; 
Fabre et al., 2007; Hunter et al., 2010; Li et al., 2012; Santen, 2014). 




Notably, others have previously shown that the GR, activated by the synthetic agonist, 
dexamethasone (Dex), can mimic the AR in CRPC by activating the transcription of genes containing 
a selective ARE, thereby maintaining tumorigenesis (Arora et al., 2013). The authors defined genes 
containing a selective ARE as those which were highly expressed in the presence of DHT relative to 
those expressed in the presence of Dex. When considering that the selective ARE used in our study 
was defined as such due to it displaying selectivity for the AR instead of the GR, it is likely that the 
selective AREs defined in the Arora et al. (2013) study may be similar to the selective ARE employed 
in this study. Since it is known that a high degree of structural homology exists between the AR, GR 
and PR (Gao et al., 2005), it was not surprising that the PR isoforms, like the GR, could mediate 
transactivation on the selective ARE (Fig. 3.3-3.4; 3.15-3.16). These results suggest that the PR 
mimics AR activity on both the classical and selective AREs and may explain why prostate cancer 
patients with increased PR expression are more likely to exhibit treatment failure and higher tumour 
grade (Bonkhoff et al., 2001; Grindstad et al., 2015). In addition, when considering that recent data 
has shown that serum P4 levels are increased in CRPC patients treated with abiraterone acetate as 
well as enzalutamide (McKay et al., 2017; Montgomery et al., 2017), this further implies a mechanism 
by which the activated PR may mediate oncogenic effects in CRPC. 
 No proliferation of the MDA-MB-231 and PC3 cell lines was observed  
It is known that the transactivation of genes aid in the regulation of cell proliferation in cancer 
(Nicholson et al., 1995). Since we observed changes in AR transactivation in the presence of the PR 
isoforms, we next wanted to investigate how the PR isoforms would affect AR-mediated effects on 
cell proliferation. Using both the MTT and Alamar blue cell proliferation assays, we first aimed to 
investigate the effects of the AR on proliferation of the MDA-MB-231 and PC3 cell lines transiently 
transfected with the AR. However, no proliferation was observed in the presence of DHT in either 
cell line (Fig. 3.17) and we could thus not investigate the putative effects of the PR isoforms on  
AR-mediated proliferation. Results from previous studies investigating the effects of DHT on the 
proliferation of MDA-MB-231 cells transfected with the AR are contradictory. While one study has 
shown proliferative effects (Shen et al., 2017), others have indicated that introduction of the AR into 
the MDA-MB-231 cell line caused decreased cell proliferation (Garay et al., 2012; Narayanan et al., 
2014). Similarly, studies investigating changes in PC3 cell proliferation are contradictory, with a 
study reporting an increase in cell proliferation upon introduction of the AR (Yuan et al., 1993), while 
others report a decrease or no effect in PC3 cell growth (Lin et al., 1998; Peng et al., 2008; Schweizer 
et al., 2008; Zeng et al., 2011). These discrepancies in findings may be due to differences in the 
amount of AR transfected into the cells or different experimental conditions. For example, studies 




showing that the AR decreased proliferation in the MDA-MB-231 cell line used cells stably 
overexpressing the AR and treated with DHT for 72 hours (Garay et al., 2012; Narayanan et al., 
2014), while the study showing a decrease in cell proliferation transiently transfected the AR and 
treated with DHT for 48 hours (Shen et al., 2017). Notably, one of the studies showing decreased 
proliferation of PC3 cells transiently transfected with the AR transfected more than forty times less 
AR than used in this study (Zeng et al., 2011), while the other transfected forty times more (Schweizer 
et al., 2008).  
 Conclusions and future work 
It is widely accepted that androgen signalling via the AR maintains prostate cancer tumorigenesis, 
however, the role of the AR in breast cancer is less straightforward and seems to depend on the 
presence of ERα (Proverbs-Singh et al., 2015). However, breast and prostate cancers also express 
others steroid receptors such as the PR (Brisken, 2013; Grindstad et al., 2015), and emerging evidence 
suggests considerable interplay between these steroid receptors in breast cancer (Claessens and Tilley, 
2014; Sikora, 2016). Although the role of steroid receptors and their interplay is an area of ongoing 
research, studies in breast cancer have shown both good and bad prognosis associated with receptor 
crosstalk. For example, the AR has been shown to decrease ERα activity suggesting a protective role 
for the AR (Peters et al., 2009), while the activated PR is also protective as it redirects ERα chromatin 
binding such that ERα-mediated proliferative responses are inhibited (Mohammed et al., 2015). In 
contrast, the AR has been shown to sustain tumorigenesis in a post-menopausal model of ER+/PR+ 
breast cancer, possibly by regulating PR expression, as well as through ER-AR crosstalk  
(Wellberg et al., 2017). Although some studies have suggested a possible interplay between the AR 
and ERβ (Muthusamy et al., 2011; Grubisha and DeFranco, 2013) in prostate cancer, the role of 
steroid receptor crosstalk in prostate cancer is not well-described. To the best of our knowledge, this 
study is the first to show that both PR isoforms can modulate AR transactivation function on the 
classical and selective AREs, as well as the ERE, in both breast and prostate cancer cell lines. In 
addition, we provide novel evidence that the PR isoforms, particularly the more transcriptionally 
active PRB, mimic AR activity on the selected response elements. In terms of prostate cancer, the 
results presented in Chapter 3 thus provide impetus to clinical studies reporting that high PR 
expression in prostate cancer is a poor prognostic factor (Bonkhoff et al., 2001; Grindstad et al., 
2015). Furthermore, the results showing that the AR and PR isoforms can transactivate via the ERE 
in the MDA-MB-231 cell line may provide a mechanism through which these receptors can mediate 
resistance to breast cancer treatments (Hopp, 2004; De Amicis et al., 2010; Rechoum et al., 2014; 
Ciupek et al., 2015).  




Overall, we observed that PRB, whether in the absence or presence of PR ligands, generally 
upregulated AR transactivation on the various response elements, including the ERE through which 
ERα mediates oncogenic actions in breast and prostate cancer. These results suggest that PRB may 
enhance AR-mediated oncogenic effects in prostate and/or breast cancer by increasing the expression 
of genes containing the selective ARE sequence in prostate cancer, or ERE sequences in both prostate 
and breast cancer. While AR transactivation function was also increased by PRA on the selective 
ARE and ERE, PRA decreased AR-mediated transactivation on the classical ARE. Understanding 
the role of PRA is thus more complex than that of PRB. Although PR expression is increased in 
prostate cancer, the relative expression levels of the PR isoforms is unknown (Grindstad et al., 2015). 
In contrast, several studies have shown that the upregulation of PRA relative to PRB in breast cancer 
is associated with poor prognosis (Hopp, 2004; Bellance et al., 2013; Wargon et al., 2015). Our results 
show that PRA may increase tumorigenesis in both breast and prostate cancer by increasing  
AR-mediated transactivation of target genes containing the selective ARE and ERE. On the other 
hand, PRA may decrease oncogenic effects of the AR on target genes containing the classical ARE. 
Further studies are needed to investigate the physiological implications of these results. 
To gain further insights into the results observed in Chapter 3, future studies could aim to understand 
the ligand-specific effects observed with P4 and MPA in the different cell lines. Molecular docking 
simulations have previously been employed to examine conformational changes in the AR when 
bound to different ligands (Africander et al., 2014). Similar studies can thus be used to further 
investigate the conformational change induced in the PR isoforms with different ligands. In addition, 
it could be investigated whether the cell-specific effects observed in this study may be due to 
differential metabolism of the ligands and/or due to differential interaction(s) of transcriptional co-
regulators with the steroid receptors in the two cell lines. Metabolism could be investigated using 
liquid chromatography tandem mass spectrometry. To investigate the interaction between specific 
co-regulators and the AR and/or PR isoforms, the mammalian two-hybrid assay, commonly used to 
investigate protein-protein interactions, could be employed (He and Li, 2008). This technique could 
also be employed to investigate the direct interaction that we hypothesise occurs between the AR and 
PRB or PRA. Förster resonance energy transfer (FRET) studies can also be used to confirm the results 
from the mammalian two-hybrid assay, by tagging the AR and PRB or PRA with the FRET coupled 
yellow fluorescent protein (YFP) and cyano fluorescent protein (CFP) (Sekar and Periasamy, 2003).  
It would be interesting to determine whether the effects observed on the synthetic promoters in this 
study translate to a more physiologically relevant system. Using quantitative real-time polymerase 
chain reaction (qPCR), effects could be investigated on endogenous genes implicated in breast and/or 
prostate cancer development and progression. Examples of genes are the PR target gene, GATA3 that 




contains a PRE/classical ARE sequence within its promoters (Lai et al., 2009; Yin et al., 2012), the 
AR target gene, PSA that contains both a PRE/classical ARE sequence and a selective ARE sequence 
(Lai et al., 2009), and genes containing an ERE sequence such as the anti-apoptotic bcl-2 and tumour-
suppressive p53 genes (Ikeda et al., 2015). Furthermore, to gain more insight into our hypothesis that 
both the AR and PR isoforms are responsible for the increased transactivation observed in Chapter 3, 
chromatin immunoprecipitation (ChIP) assays could be performed to firstly determine whether the 
AR or PRB or PRA are recruited to the various response elements in the promoters of the above-
mentioned endogenous genes. The ChIP assay uses receptor-specific antibodies and primers 
recognizing specific DNA sequence to study the interaction between a protein and a specific DNA 
sequence in vivo (Gade and Kalvakolanu, 2012). To establish whether the AR and PRB or PRA are 
co-recruited to the promoter of these genes, sequential ChIP (re-ChIP) assays could be performed 
This technique is based on the same principle as the ChIP assay, but involves two 
immnoprecipitations with two different antibodies (Truax and Greer, 2012).  
Finally, as we were unable to show the effects of the AR on breast and prostate cancer cell 
proliferation, and thus the effects of the PR isoforms on AR-mediated proliferation, future studies 
could aim to optimise the cell systems in terms of the amount of receptor to be transfected and 
experimental conditions such as incubation time. In addition, cell proliferation studies could be 
performed in cell lines expressing endogenous AR and PR, such as the T47D breast cancer cell line 
or the LNCaP prostate cancer cell line (Lai et al., 2009). The roles of the individual receptors could 
be determined by silencing the expression of the AR or PR using small interfering RNA (siRNA) 
technology.  
In summary, the results from this study show that the PR can mimic AR transactivation function and 
that AR-PR crosstalk is indeed possible, occurring in a cell-, ligand- and PR concentration-specific 
manner. These results emphasise the fact that ligands may induce a conformational change within 
steroid receptors, which may lead to not only ligand-specific, but also promoter-specific effects, 
depending on the cellular milieu. Finally, although the results from this study are preliminary, the 
complexity of the role of steroid receptors in breast and prostate cancer are highlighted, and may 
fortify studies showing that the AR and PR mediate tumour progression and treatment failure in breast 
and prostate cancer. 
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2x Laemmli SDS-sample buffer  
100 mM Tris-HCl at pH 6.8 
20% v/v glycerol 
5% w/v SDS 
0.1% w/v bromophenol blue 
2% v/v β-mercaptoethanol 
Adjust to a final volume of 25 ml using reverse osmosis (RO) water. 
 
Charcoal stripping buffer 
0.2 M sucrose 
10 mM Hepes 
1.5 mM MgCl2 hexahydrate 
0.25% w/v Norit-A charcoal 
0.025% w/v Dextran 
Adjust to a final volume of 1 L using autoclaved deionised water. 
 
Luria Bertani (LB) broth 
1% w/v NaCl 
1% w/v tryptone 
0.5% w/v yeast extract 
Adjust to pH 7.5. 
Adjust to a final volume of 1 L using RO water. 











Passive lysis buffer 
0.2% v/v Triton X-100 
10% v/v glycerol 
2.8% v/v Tris-phosphate-EDTA 
1.44 mM EDTA 
Adjust to a final volume of 1 L using RO water. 
 
SDS-PAGE running buffer 
35 mM SDS 
250 mM Tris-HCl 
1.92 M glycine 
Adjust to a final volume of 1 L using RO water. 
 
Transfer buffer 
25 mM Tris-HCl 
192 mM glycine 
10% v/v methanol 











Super optimal broth medium with catabolite repression (SOC) 
2% w/v tryptone 
0.5% w/v yeast extract 
10 mM NaCl 
2.5 mM KCl 
20 mM MgCl2 
20 mM glucose 
Adjust to a final volume of 1 L using RO water and sterilise by autoclaving. 
 
Tris-EDTA (TE) buffer 
10 mM Tris/HCl 
1 mM EDTA 
Adjust to pH 8.0. 
Adjust to a final volume of 100 ml using RO water. 
 

























Figure S1: Restriction enzyme digests of plasmid DNA confirm plasmid DNA integrity and size. Digested and 
undigested plasmid DNA was separated on a 1% agarose gel electrophoresis. Lane 1 of A, B and C contains the 
O’GeneRuler 1kb DNA ladder (ThermoFisher Scientific, South Africa). A detailed description of each lane is provided 
above each figure, where ‘U’ represents the undigested plasmid and ‘D’ the digested plasmid.  
 





Figure S2: The PC3 and MDA-MB-231 cell lines used for experiments are mycoplasma negative. Representative 
images indicate that the PC3 (A) and MDA-MB-231 (B) cell lines are mycoplasma negative as determined by the Hoechst 
staining technique (Freshney, 2010). Mycoplasma negative cells were visualised using the Olympus IX81 inverted 
fluorescent microscope for live cell imaging at Stellenbosch University CAF. 
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